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                       Abstract 
The first section of this thesis deals with the synthesis of substituted quinolines and 
its bioactivities against gap junction. Cancer cells are characterized by down regulated 
or altered gap junction intercellular communication (GJIC) activities; enhancement of 
GJIC would provide a pathway for the delivery of anticancer drugs. Our computational 
studies using Autodock found binding interactions between gap junction channels and 
substituted quionlines (code name PQs). Thus, a serial of PQ compounds were 
synthesized and their activities against GJIC were tested. Among these synthesized 
PQs, 6-Methoxy-8-[(3-aminopropyl) amino]-4- methyl-5-(3-trifluoromethyl- 
phenyloxy)quinoline (PQ1) can specifically enhance GJIC activity of T47D cells 
without affecting the normal MECs. The PQ1 induced apoptosis can spread throughout 
the gap juctions, consequently cause the decrease of cell viability and colony growth. 
PQ1 can attenuate tumor growth of xenograft tumors in Nu/Nu mice. Compound 7 
(code PQ11) which has an IC50 of 15.6nM against T47D cancer cell, is a promising 
candidate for further pharmacological studies.  
 
  The second section of this thesis deals with the synthesis and anticancer bioactivities 
of PEG-PEI based nanogels. Nanogels were synthesized, encapsulated with anticancer 
drugs, and loaded to stem cells. Stem cells can target at the cancer cell and release the 
nanogel and anticancer drug to kill the cancer cell. The nontoxic PEG-PEI nanogel 
which can be loaded to stem cells was successfully synthesized by doubly treatment of 
PEI with activated PEG. Based on this nontoxic nanogel, two other types of nanogels 
were synthesized. In one type of nanogel, an anticancer drug, SN38 was modified and 
attached to the nontoxic nanogel via a tetra-peptide linker. This tetra peptide can be 
recognized and cut by legumain, a protein that highly over expressed in many tumors, 
to release the drug to tumors. In the other type of nanogel, straptavidin was attached to 
the nanogel which can bind to biotin and recognized by tumor.  The result indicated 
this type of nanogel can be loaded to stem cells within 15 minutes. 
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 Abstract 
  The first section of this thesis deals with the synthesis of substituted quinolines 
and its bioactivities against gap junction. Cancer cells are characterized by down 
regulated or altered gap junction intercellular communication (GJIC) activities; 
enhancement of GJIC would provide a pathway for the delivery of anticancer drugs. 
Our computational studies using Autodock found binding interactions between gap 
junction channels and substituted quionlines (code name PQs). Thus, a serial of PQ 
compounds were synthesized and their activities against GJIC were tested. Among 
these synthesized PQs, 6-Methoxy-8-[(3-aminopropyl) amino]-4- 
methyl-5-(3-trifluoromethyl- phenyloxy)quinoline (PQ1) can specifically enhance 
GJIC activity of T47D cells without affecting the normal MECs. The PQ1 induced 
apoptosis can spread throughout the gap juctions, consequently cause the decrease of 
cell viability and colony growth. PQ1 can attenuate tumor growth of xenograft tumors 
in Nu/Nu mice. Compound 7 (code PQ11) which has an IC50 of 15.6nM against T47D 
cancer cell, is a promising candidate for further pharmacological studies.  
 
  The second section of this thesis deals with the synthesis and anticancer bioactivities 
of PEG-PEI based nanogels. Nanogels were synthesized, encapsulated with anticancer 
drugs, and loaded to stem cells. Stem cells can target at the cancer cell and release the 
nanogel and anticancer drug to kill the cancer cell. The nontoxic PEG-PEI nanogel 
which can be loaded to stem cells was successfully synthesized by doubly treatment of 
PEI with activated PEG. Based on this nontoxic nanogel, two other types of nanogels 
were synthesized. In one type of nanogel, an anticancer drug, SN38 was modified and 
attached to the nontoxic nanogel via a tetra-peptide linker. This tetra peptide can be 
recognized and cut by legumain, a protein that highly over expressed in many tumors, 
to release the drug to tumors. In the other type of nanogel, straptavidin was attached to 
the nanogel which can bind to biotin and recognized by tumor.  The result indicated 
this type of nanogel can be loaded to stem cells within 15 minutes.
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CHAPTER 1-Synthesis and Bioactivities of Substituted 
Quinolines  
 
1.1 Introduction 
Gap junctions are channels that connect two adjacent cells. Gap junctions are 
important channels1 for the communication between cells as they allow a variety of 
compounds to pass through such as water, ions, metabolites, and secondary 
messengers which are smaller than 1000 Daltons.1 
For normal cells, gap junction intercellular communication (GJIC) is highly up 
regulated. The apoptosis or damage signals can pass through the gap junction as well 
as other small molecules. Moreover, some diseases are associated with an increase in 
gap junction intercellular communication.16 It is therefore necessary to find a 
compound that can specifically inhibit the gap junction activities.  
One major difference between normal cells and cancer cells is the gap junction 
intercellular communication (GJIC). Cancer cells are mostly characterized by reduced 
or altered gap junction activities. Because of the lack of gap junction intercellular 
communication, the apoptosis signals can’t be passed over to the cancer cells.11 
Moreover, the anti-cancer drugs can only kill cancer cells on the tumor surface which 
results in the demand of a large dose. In this case, it is important to find a gap junction 
enhancer that can increase or restore the gap junction intercellular communications 
between cancer cells to provide a pathway for apoptosis signals and anticancer drugs to 
penetrate to the inside of tumor.  
   Quinolines have been shown to have anticancer activities.17-19 The effects of 
quinolines in modulation of multidrug resistance,17 targeting tumor hypoxia,18 and 
inhibition of tyrosine kinase19 have been reported. Substituted quinolines were 
therefore examined to determine their interaction with gap junctions. Our 
computational docking study indicated binding between the substituted quinolines and 
the gap junctions.  
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    A series of substituted quionlines (code name PQs) were synthesized in this study, 
and their activities on gap junctions were evaluated. The effect of PQ1 on the 
enhancement of gap junction on retinal and neuronal cells was studied using Lucifer 
yellow dye transfer assay, and the effect of PQ1 on the cell viability and colony growth 
of T47D breast cancer cell line was evaluated. On contrary to that of retinal and 
neuronal cells, the results indicated that PQ1 enhances gap junction activity and 
activates apoptosis leading to breast cancer cell death. 
 
1.2 Background 
1.2.1 Gap Junction Intercellular Communication 
Gap Junctions function as the intercellular communication channels by allowing a 
passage for a variety of ions, small molecules secondary messengers and metabolites.  
In vertebrates, each gap junction is composed of two connexons from two different 
cells. Each connexon is composed of six proteins of the connexin (Cx) family such as 
Cx 43 and Cx 32.  For example, six Cx 43 proteins can form a connexon. To date 
approximately 21 of the connexins have been identified.2  
Commonly, the connxin monomer has four helical bundles that are connected by two 
extracellular loops and one intracellular loop. These four transmebrane domains (TM1, 
TM2, TM3, and TM4) are believed to have different functions in the gap junction 
assembly, although their mechanisms still remain unclear. The N-terminus connected 
to TM1 is shorter compared to the C-terminus that binds to TM4.5  
The phosphorylation of connexin mostly occurs on the serines3 of the C-terminus 
and this phosphorylation process is shown to have important effect on the regulation of 
gap junction intercellular communication. The higher the expression of 
phosphorylated form of connexin, the lower the regulation of gap junction is 
observed.4  
 - 3 - 
 Figure 1 gap junction http://psychology.wikia.com/wiki/Connexon 
 
The connexins follows the dimmer-dimmer pathway6 to oligomerize into connexons. 
These connexons are then transported through the Golgi and fused to the nonjunctional 
plasma membrane. The connexons travel to the edge of the gap junction plaque where 
new gap junction channels were formed.7, 8 
Gap junctions allow a variety of compounds to pass through including secondary 
messengers. Apoptosis or damage signals can also be passed from the damaged cell to 
its adjacent normal cells, which can spread out the damage. Researchers are thus trying 
to find ways to prevent this effect. One possibility is to block the gap junctions 
between the normal cells and the affected cells.  Moreover, some of the diseases are 
associated with the increase of the gap junction intercellular communication (GJIC), 
which can be possibly treated by reducing the GJIC.  Those compounds that can 
effectively block or inhibit the activities of gap junction channels are called gap 
junction inhibitors or blockers.  
One significant difference between the normal cells and cancer cells is the amount of 
gap junctions. Unlike the normal cells that can communicate intracellularly through 
the gap junction channels, cancer cells are characterized by the lack of gap junctions. 
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As shown in figure 2, the initiated cell is suppressed by the surrounding normal cells, 
but the functional gap junctions are then disrupted by the cancer cell. The cancer cell 
that is released from the suppression grows to become a tumor without regulation.10 
Because of the lack of gap junction intercellular communication, the apoptosis signals 
can’t be passed over to the cancer cells.11 Moreover anti-cancer drugs could only kill 
the cancer cells on the tumor surface which results in the demand of a large dose. 
In this case, it is necessary to open or restore the gap junction intercellular 
communication. The restoration of the gap junction can provide a pathway for the 
apoptosis signal to be delivered to the cancer cells. On the other hand, the anti-cancer 
drugs can also gain entrance into the internal part of the tumors, which resulted in an 
increase in drug sensitivity. 
 
Figure 2 Disruption of GJIC in cancer cells 
 
 
1.2.2 Gap Junction Inhibitors and Enhancers 
Very few compounds have been reported to be gap junction inhibitors9, 12, 16 or 
enhancers13, 14, 15 despite the extensive research that has been done in this field.   
Glycyrrhetinic acid, a derivative of the natural product glycyrrhizic acid isolated 
from the Chinese herb liquorice, is known to be an inhibitor of the gap junction. Its 
analog, carbenoxolone has also shown this inhibitory effect. To date no total synthesis 
of carbenoxolone has been reported. Resveratrol, a compound reported by Jiang14 in 
1997 that can prevent the skin cancer, has been discovered to be a gap junction 
enhancer.  
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1.2.3 Interaction of GJIC with Substituted Quinolines 
Quinolines have been shown to have anticancer activities.17-19 The effects of 
quinolines in modulation of multidrug resistance,17 targeting tumor hypoxia,18 and 
inhibition of tyrosine kinase have been reported.19 Hence, substituted quinolines were 
examined on the interaction with gap junctions. To find new compounds that can 
interact with GJIC, the partial crystal structure of gap junction20-22 was utilized as a 
model to develop new drugs. By using Autodock computational docking software,23-25 
the bindings of substituted quinolines (code name PQs) to the inert core of the 
hexameric hemichannel of gap junctions were observed. In one of the minimum 
energy (-0.7 kcal/mol) bound structures, interactions (close contact) between CF3 
group of PQ1 and H-N of Leu144 of connexin (2.5 Å), and OCH3 group of PQ1 and 
CH2 of Phe81 of connexin (2.0 Å) were found. Consequently, this substituted 
quinoline and its analogs were synthesized and their GJIC and anticancer activities 
were studied. 
 
 
 
 
Figure 3 Interactions between PQ1 and GJIC by computational docking. In one of the 
minimum energy (-0.7 kcal/mol) bound structures, interactions (closed contact) 
between CF3 group of PQ1 (blue) and H-N of Leu144 (green) of connexin (2.5 Å), 
OCH3 group of PQ1 and CH2 of Phe81 (orange) of connexin (2.0 Å), and NH3+ of PQ1 
and –O2C-Glu146 of connexin are found  
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1.3 Synthesis of Substituted Quinolines 
The synthesized substituted quinolines are summarized in Figure 4. 
MeO
O
NHR
F3C
N
CH3
Figure  4.  Structural formulas of substituted quinolines
  1 :  R = CH2CH2CH2NH2
  2 :  R = CH2CH2CN
  3 :  R = CH2CH2C(=NH)OCH2CH3
  4 :  R = CH2CH2C(=NH)NH2
  5 :  R =
N
NH
H2C
  6 :  R =
  7 :  R =
S
H2C
O
H2C
 
1.3.1 Retro synthesis of compound 1 
Gabriel synthesis is a synthetic method to make primary amines from alkyl halides. 
Compound 1 was synthesized from intermediate 16 by using a Gabriel synthesis, in 
which compound 16 was reacted with 3-iodopropylphthalimide followed by a 
treatment of hydrazine to afford a primary amine. Doebner-Miller reaction was utilized 
to construct the quinoline 16 from compound 13. When treated with sodium 
bicarbonate in DMF, compound 13 undergo a Michael addition with methyl vinyl 
ketone followed by aromatization; further reduction of nitro group would give 
compound 16. Compound 13 was obtained from functionalizations of 
N-(4-methoxyphenyl) acetamide (8). Bromination at C2 and nitration at C5 followed 
by deprotection of acetyl of starting compound 8 led to intermediate 13.  
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MeO
N
O
HN
F3C Me
NH2
1
16
MeO
N
O
NH2
F3C Me
MeO
NH2
13
O
NO2
CF3MeO
NHCOCH3
8
Scheme 1 Retro-synthesis of compound 1
 
 
1.3.2 Synthesis of 4-amino-5-nitro-2-(3-trifluoromethylphenyloxy) anisole 
A similar synthetic strategy was utilized from the literature reports26, 27 with some 
modification. Starting from N-(4-methoxyphenyl) acetamide (8), functionalizations on 
C2 and C5 lead to the synthesis of 4-amino-5-nitro-2- 
(3-trifluoromethylphenyloxy)anisole (13) (scheme 1). Bromination of compound 8 at 
C2 in acetic acid using bromine gave N-(3-bromo-4-methoxyphenyl) acetamide (9) in 
69% yield after recrystallized from 25% ethanol in water. Nitration of 9 at C5 by using 
nitric acid in acetic anhydride and acetic acid at 5°C for 3 hours gave 
2-bromo-4-acetamino-5-nitroanisole27 (10) in 82% yield after recrystallized from 
chloroform. 4-acetamino-5-nitro-2-(3-trifluoromethyl- phenyloxy) anisole (12) was 
prepared by a substitution of bromide in compound 10 with potassium 
3-trifluoromethylphenoxide (11) in N, N-dimethylformamide (DMF) at 120 oC; the 
yield of this reaction was 79% after recrystallized from ethanol.  The acetyl 
proctetction group of 12 was removed with hydrochloric acid in ethanol followed by 
recrystallization from ethanol to give 4-amino-5-nitro-2-(3-trifluoro- methylphenyloxy) 
anisole (13) with 95% yield.  
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MeO
NHCOCH3
Br2, AcOH
(69% yield)
8
KO CF3
DMF, 120oC
(79% yield)
11
HCl. EtOH
(95% yield)
Scheme 2.  Preparation of 4-amino-5-nitro-2-(3-trifluoromethylphenyloxy)anisole (13)
HNO3, Ac2O
   AcOH
(82% yield)
MeO
NHCOCH3
9
Br
MeO
NHCOCH3
10
Br
NO2
MeO
NHCOCH3
12
O
NO2
CF3
MeO
NH2
13
O
NO2
CF3
 
1.3.3 Synthesis of 6-Methoxy-4-methyl-8-nitro-5-(3-trifluoromethyl 
phenyloxy)quinoline (14) 
Literature28 has reported the construction of the quinoline via a Michael addition of 
vinyl methyl ketone.  However, the results turned out not as simple as was reported. 
Vinyl methyl ketone was added to a solution of 13, arsenic acid in 85% phosphoric 
acid at 100 oC (oil bath temperature); the color of the solution turned from red to dark 
brown immediately after the addition. After 20 minutes, the reaction29 was worked up 
and a mixture of desired quinoline 14 and 1, 4-adduct 15 as well as the starting material 
13 was obtained in a ratio of 1:2:1. A 24.5% yield of compound 14, 49% yield of 
compound 15, and 24% recovery of 13 were obtained after the separation by silica gel 
column chromatography. A higher temperature (120 oC) did not improve the yield of 
compound 14, but resulted in decomposition of 1, 4- adduct 15 and starting material 13 
and longer reaction time had the same effect. Excess of vinyl methyl ketone did not 
result in the decomposition; however the yields and ratios remained unchanged neither. 
Compound 15 was then treated with arsenic acid in phosphoric acid again under 
similar conditions as that mentioned above to give 14 and 13 along with the starting 
material 15 in a ratio of 1:2:1. The results indicated that the intermediate 15 can either 
undergo a cyclization to form the desired product 14, or a reverse Michael addition to 
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provide amine 13 and vinyl methyl ketone.  
  Since the conjugated alkynones were also used to construct quinolines30, 31 from 
aromatic amines, 3-butyn-2-one was also tested in order to simplify the synthesis. 
Amine 13 was treated with 3-butyn-2-one and arsenic acid in phosphoric acid at 100 
oC for 20 minutes; after work up, the crude products were separated by silica gel 
column chromatography. The desired product 14 was obtained in a 24% yield along 
with 28% of recovered starting material 13 while the 1, 4-adduct was not detected. 
Instead, some red oligomers that can not be identified by NMR spectroscopy were 
obtained. This might due to polymerization of the alkynone or rapid decomposition 
of the 1, 4 adduct. Thus, vinyl methyl ketone was chosen to construct the quinoline 
ring since the 1, 4-adduct could be isolated and retreated to improve the overall yield 
of compound 14. 
 
vinyl methyl ketone
H3AsO4
85% H3PO4
100oC, 20 min.
Scheme 3.  Preparation of quinoline 14 and 15
+
H3AsO4,  
85% H3PO4
100oC, 20 min.
15 14     +    13
13 MeO
N
H
14
O
NO2
F3C
O
MeO
N
O
NO2
F3C Me
15
3-butyn-2-one
H3AsO4
85% H3PO4
100oC (24% yield)
13 14
(24.5% yield) (49% yield)
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1.3.4 Synthesis of PQ1 (1) 
Reduction of compound 14 with iron powder in 1% (by volume) acetic acid in water 
under reflux for 2 hours gave amino quinoline 16 in 96% yield as a red solid. Base on 
the amino function group, compound 16 was served as the precursor for a series of 
different substituted quinolines as shown in Figure 1. Since compound 16 was red in 
color and strongly UV active while all the substituted quinolines had a yellow or red 
color, the purification of product by silica gel column chromatography was easily 
achieved by tracking the color. Treatment of amino quinoline 16 with Iodide 17 and 
sodium bicarbonate in DMF at 80 oC for 48 hours32 gave the alkylated compound 18 as 
a yellow solid in 72% yield. Removal of the amino protecting group of compound 18 
with hydrazine in refluxing ethanol finished substituted quinoline 1 as a yellow solid in 
80% yield. Since compound 1 had very poor solubility in aqueous media, its succinic 
acid salt was prepared by treatment with 1 equivalent of succinic acid in methanol, 
diluted with water and lyophilized to yield the succinic salt in quantitative yield. The 
code name for the succinic salt of compound 1 is PQ1. 
 
Fe, H2O
AcOH
(96% yield)
Scheme 4.  Synthesis of substituted quinoline 1(PQ1)
16
MeO
N
O
NH2
F3C Me
N
O
O
(CH2)3 I
NaHCO3, DMF(72% yield)
(17)
18
MeO
N
O
HN
F3C Me
N
O
O
H2NNH2, EtOH
(80% yield)
1
14
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1.3.5 Synthesis of PQ6-PQ8 
Compound 16 was treated with acrylonitrile in phenol at 100 oC for two days33 in a 
sealed tube to give compound 2 as a Michael addition product in 50% yield along with 
20% of recovered starting material 16. No reaction was found when ethanol34 was used 
as a solvent instead of phenol. Ethanolysis35 of compound 2 by the treatment with 
saturated HCl (gas) in ethanol and benzene in a sealed tube at room temperature for 3 
days afforded a 69% yield of ethyl imidate 3 as a yellow solid. Compound 3 was then 
treated with ammonia gas in ethanol36 at 50 oC for 6 hours in a sealed tube to produce 
amidine 4 in 57% yield along with 13% recovery of starting material 2. Their succinic 
salts were made by adding 1 equivalent of succinic acid in methanol followed by 
diluting with water and lyophilization.  The code names of the succinic salts for 
compound 2, 3and 4 were PQ6, PQ7 and PQ8, respectively. 
 
16
Phenol
100oC, 48 h
CN
(50% yield)
MeO
N
O
HN
F3C Me
CN
2
MeO
N
O
HN
F3C Me
R
3 : R = C(=NH)OCH2CH3
4 : R = C(=NH)NH2
1. EtOH, HCl
 (69% yield)
2. NH3, EtOH(57% yield)
Scheme 5. Synthesis of compounds 2-4
 
1.3.6 Synthesis of PQ9-PQ11 
 
Initially, we were trying to synthesize quinoline 5 by using nuclearphilic substitution 
of the aromatic amine 16 with 5-(chloromethyl)-1H-imidazole 19. Compound 16 was 
treated with 19 and sodium bicarbonate in DMF at 80 oC for two days, however, no 
reaction was detected. This might be due to the instability of compound 19. Imidazole 
19 can absorb moisture very rapidly and decompose at room temperature.  
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Synthesis of quinolines 5-7 was accomplished via a reductive amination37 of 
aromatic amine 16 and with an aldehyde. Treatment of 16 with aldehyde 20 in 
methanol-acetic acid for 1 hour at room temperature followed by the addition of 
sodium cyanoborohydride afforded compound 5 as a yellow solid in 79% yield. 
Aldehyde 20 was obtained by the oxidation of 5-hydroxymethylimidazole with 
manganese dioxide in methanol38 at room temperature (99% yield). Treatment of 
compound 16 with aldehyde 21 and 22 separately utilizing the same procedure as 
mentioned above gave quinolines 6 and 7, respectively. Their succinic salts were made 
by adding 1 equivalent of succinic acid in methanol followed by diluting with water 
and lyophilization.  The code names of the succinic salts for compound 5, 6 and 7 
were PQ9, PQ10 and PQ11 respectively. 
 
16
MeO
N
O
NH2
F3C Me
N
N
H
+
NaHCO3
DMF
80oC 48h
MeO
N
O
HN
F3C Me
N
N
H
19
Cl
5
Scheme 6.  Synthesis of substituted quinolines 5 ~ 7.
16      + MeO
N
O
HN
F3C MeNaBH3CN
MeOH
AcOH
Y
X
O
H
20 : X = NH, Y = N
21 : X = S
22 : X = O
Y
X
5 : X = NH, Y = N  (79% yield)
6 : X = S  (47% yield)
7 : X = O  (52% yield)
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1.4 Results and Discussions 
Breast cancer, the most common type of cancer in women worldwide, 39 is one of the 
highest death rate cancers for women in the United States.  Breast cancer cells also 
have reduced or altered gap junction intercellular communications. The growth 
activity of cancer cells is negatively related to the capability of communication40 
through gap junction; thus one feasible way to reduce the growth of tumor is to restore 
or enhance the gap junction41, 42 in breast cancer cells. A small molecule that can 
activate the GJIC would provide a possible way to load the anticancer drugs to breast 
cancer cells. Our autodocking computation shows the interaction of PQ1 with the 
connexin 43 hemichannels; thus PQ1 has been chosen and its effect on gap junctions 
has been evaluated. The bioactivity evaluations on T47D cells were done by our 
collaborator, Dr. Thu Annelise Nguyen and her student Gunjan Gakhar. The bioactivity 
on R28 cells regarding the inhibition of gap junction were tested by Dr. Dolores J. 
Takemoto and her student Satyabrata Das. 
 
1.4.1 Effect of PQ1 in GJIC in T47D Breast Cancer Cells 
The effect of PQ1 on the GJIC activity in T47D breast cancer cells was tested. 
Scrape load/dye transfer assay was utilized (Figure 5). In this experiment, the white 
dash line indicates the initial cutting site. Rhodamine-dextran, which was a relatively 
large molecular dye that can’t pass through the gap junction channels, was used to 
mark the cutting site. To the right side of the cutting site, different doses of PQ1 were 
given to the cells compared to the control. Lucifer yellow was used as a dye that can 
travel through any gap junctions that are present. The top panel shows the T47D cancer 
cell while the bottom shows the normal cell. For the control with media alone or 
treated with succinic acid, the Lucifer yellow (green in color) can’t travel to the right 
side due to the lack of gap junction. When treated with PQ1, the travel of the Lucifer 
yellow was obviously increased as the concentration of PQ1 increased. The results 
indicated that PQ1 can significantly increase the gap junction activity in T47D cells 
compared to the control using scrape load/dye transfer assay (Figure 5A, top panels). 
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While for the human primary epithelial cells (MEC, normal cells, Figure 5A, bottom 
panels), the Lucifer yellow dye were uniformly transferred due to the existing high 
level of gap junction activity43-45 in these cells. A graphical representation 
demonstrated that 200 nM PQ1 causes an 8.5-fold increase in distance of dye transfer 
compared to control (Figure 5B).  
 
Figure 5. Effect of PQ1 in Gap Junction Activity (data collected from Dr. Thu 
Annelise Nguyen and Dr. Gunjan Gakhar). A top) T47D and A bottom) MEC cells 
were treated with 0, 100, 200, and 500 nM PQ1 for 1 hour. Controls are media alone 
and succinic acid. B) Graphical presentation of experiments shows the distance of dye 
transfer of T47D cells. 
 
1.4.2 Effect of PQ1 in T47D Cancer Cell Colony Growth 
The above result on the GJIC of T47D breast cancer cells indicated that PQ1 can 
cause an increase in the GJIC activities of T47D cells. For most cancer cells, the cell 
growth ability is related to the GJIC, the higher the GJIC in cancer cells, the lower the 
growth of cancer cells. Thus, we would expect that PQ1 can inhibit the growth of 
T47D breast cancer cells by enhancing the GJIC.  
The effect of PQ1 in T47D cancer cell colony growth formation was examined. As 
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shown in Figure 6, T47D and MEC cells were treated with 10, 100, 1000, and 10,000 
nM PQ1 for 7 days. Individual cell colonies which were larger than 50 µm were 
counted. A graphical presentation of three experimental results is presented below in 
log scale of PQ1 concentration. The treatment of 100 nM PQ1 inhibited 66% of colony 
growth compared to the control, while having no effect on the normal cells. This 
suggested that treatment of PQ1 can increase the GJIC activity and subsequently 
decrease colony growth of T47D cells. 
 
Figure 6 Effects of Substituted Quinolines on T47D and MEC Cells (data collected 
from Dr. Thu Annelise Nguyen and Dr. Gunjan Gakhar). Base agar plates were 
prepared containing 0.8% agar and 0.4% agar in Ham’s F12. Cells (5 × 104 cells/33 
mm2 well) were suspended in 100 µl of Ham’s F12 with 0.4% agar and plated. These 
plates were maintained at 37°C for 7 days and examined for the presence of colonies. 
Individual colonies of 50 µm or greater were examined. T47D cells were treated with 1, 
10 and 100 nM PQ1 and SA (succinic acid) as a solvent control. Individual colonies of 
50 µm or greater were examined. Statistical significance, *p<0.05, of at least three 
experiments. 
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1.4.3 Effect of PQ1 on Cell Viability 
PQ1 restored the GJIC on T47D cells, and caused a decrease in the colony growth 
of T47D breast cancer cell. This indicated an inhibition of the tumor growth. As for the 
treatment of cancer cells, the cell viability is another important factor. Would PQ1 kill 
the T47D cells to cause an inhibition of the colony growth? 
Thus the cell viabilities of PQ1 in T47D and MEC cells were also determined by 
using MTT assay. Results demonstrated that at 200nM PQ1 has 67% cell viability 
compared to the controls (Figure 7). 1 µM PQ1 can further decrease cell viability to 
50% in T47D cells; however, treatments of 100 and 200 nM PQ1 have 95% and 103% 
MEC cell viabilities respectively as compared to the control. This indcated PQ1 had no 
cytotoxic effect to normal MECs even at 500 nM. 
 
 
Figure 7 Effect of PQ1 on Cell Viability (data collected from Dr. Thu Annelise 
Nguyen and Dr. Gunjan Gakhar). T47D and MEC cells were treated with various 
concentrations of PQ1 for 24 hours. MTT assay was performed with adherent cell 
cultures using a culture medium free of phenol red and of serum. Solution containing 
MTT was metabolized by the cells (incubation period 3 hours). After solubilization of 
the MTT crystals with the solubilization solution MTT, the amount of dye was 
measured spectrophotometrically at 540 nm. 
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1.4.4 Effect of PQ1 on the Expression of Connexins 
Gap junctions are composed of connexins (Cx). To date, about 20 different 
connexins have been identified. The nominations are based on the structure and 
molecular weight; for example, Cx43 is a connexin protein with a molecular weight at 
about 43 kDa.  
Not much research has been done in the study of different functions of connexins. 
The most common studied connexins are Cx26, Cx32, and Cx43 which are shown to 
be related to the bioactivities of cancer cells. In most cancer cells, the connexins are 
well expressed but can not assemble together to form gap junctions. Examination of 
the changes of connexins on T47D breast cancer cells when treated with PQ1 may 
provide a pathway to understand the mechanism of the enhancement of gap junction 
intercellular communications. 
The analysis of changes in gap junctional proteins was performed after the treatment 
of PQ1. Three common connexins, Cx26, Cx32, and Cx43 were checked using western 
blot analysis. The results indicated that PQ1 had no effect on the expression of these 
connexins. However, a decrease in phosphorylated Cx43 was observed when T47D 
cells were treated with 500 nM PQ1. This indicated that PQ1 can cause a direct 
decrease in phosphorylation of Cx43 without affecting the expression of connexins. 
The increase of GJIC (Figure 5) was consistent with the decrease of phosphorylation of 
Cx43 since upregulation of GJIC activity was dependent on the unphosphorylated 
connexins. 
 
1.4.5 Effect of PQ1 on Active Caspase 3 
When treated with PQ1, T47D cells were under apoptotic conditions sincee 
mitochondrial damage was observed. Thus the effect of PQ1 on apoptosis was 
evaluated by detecting the active form of caspase 3. A 200 nM PQ1 caused a 1.5-fold 
increase of active caspase 3 compared to the control. The decrease of caspase 3 at 
higher concentration was due to the cytotoxic response of the cells. This result 
indicated that PQ1 can induce apoptosis to T47D cells. 
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1.4.6 Effect of PQ1 on Tumor Growth in Nu/Nu Mice 
The above results demonstrated that PQ1 can enhance the GJIC activities on T47D 
breast cancer cells and inhibit the cell and colony growth at nM scale. The anti-tumor 
effect of PQ1was also tested in animal model (Figure 8). Nu/Nu mice were injected 
with T47D breast cancer cells. After the xenograft tumor grown to a certain size, a 1 
µM PQ1 or 10 µM tamoxifen (a known drug used for comparison) was injected 
directly into the tumor. The three control animals along with a tamoxifen-treated 
animal were euthanized after day 6 due to the systemic abnormality. The PQ1-treated 
group demonstrated a decrease in tumor size compared to control, even at day 2. A 
70% decrease of tumor growth with PQ1 treatment for only one injection was observed 
at day 6 compared to control. This indicated that PQ1 is a promising anti-cancer drug 
for the T47D breast cancer.  
 
Figure 8 Xenograft Tumor Growths of T47D Cells in Nu/Nu Mice (data collected 
from Dr. Thu Annelise Nguyen and her student Gunjan Gakhar). Mice was inoculated 
with 17ßestradiol (1.7 mg/pellet) before the injection of 1 x 107 T47D cells 
subcutaneously into the inguinal region of mammary fat pad. Animals received 
treatment at 1 µM PQ1 or 10 µM tamoxifen. The results after 6 days of injection show 
a decrease in tumor growth of PQ1-treated animals compared to control or tamoxifen. 
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1.4.7 Anti-tumor Effects of PQ analogs 
Since the PQ1 demonstrated a promising anti-tumor effect on T47D breast cancer 
cells, the quinolines 1-7 were tested against T47D cells using trypan blue exclusion 
assay. Among these compounds, The IC50 of quinoline 7 is 15.6 nM (Table 1), even 
lower than PQ1 which is 119 nM. The study of anti-cancer effects of compound 7 is 
now carrying on in Dr. Thu Annelise Nguyen’s lab. 
   
Compound 1 2 3 4 5 6 7 
IC50 value 
(nM) 
119 ± 
21 
378 ± 
79  
1974 ± 
404 
519 ± 
102 
1276 ± 
246 
3732 ± 
696  
15.6 ± 
3.0 
Table 1 Cell Viabilities using Trypan Blue Exclusion (data collected from Dr. Thu 
Annelise Nguyen and her student Gunjan Gakhar).  T47D breast cancer cells were 
treated with various concentrations of 1 – 7 for 2 days.  A cell suspension was mixed 
with trypan blue dye and then visually examined to determine whether cells take up or 
exclude dye.  The numbers of live cells (excluded dye) were quantified and IC50 
values for each compound were determined.   
 
Retinal ischemia46-48 is a major cause of vision loss. The apoptotic signals will pass 
from ischemic cells to adjacent normal cells via gap junction, resulting in the spread of 
damage.49 A gap junction inhibitor50-54 that can block the GJIC may provide a way to 
prevent further damage during ischemia. PQ1 was sent to Dr. Dolores J. Takemoto and 
Satyabrata Das to test the effect on gap junction activities on R28 retinal normal cells. 
1.4.8 Effect of PQ1 on Retinal R28 Cells 
Based on the computational docking23-35 results, the binding between PQ1 and gap 
junction hemi channels indicated that the quinoline compounds could be potential gap 
junction inhibitors. Thus, PQ1 and its analogs were tested for the gap junction 
activities on normal retinal R28 cells. Lucifer yellow dye transfer experiments were 
carried out on R28 cells. For the control (Figure 9A top panel), no PQ1 was loaded, 
which allowed the dye to be transferred far from the loading site to the right suggesting 
a high level of gap junction intercellular communication. While for PQ1 treatment 
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(Figure 9A bottom), the dye transfer was much less pronounced due to the inhibition of 
GJIC.  The results (Figure 9) demonstrated that after 10 µM for 40 minutes, PQ1 
inhibited the Lucifer yellow dye transfer by 90%, while mefloquine55, 56 (MQ), a 
known gap junction inhibitor, at the same dose can only inhibit 60%.   
 
 
Figure 9 PQ1 inhibition of gap junction dye transfer activity in retinal neurosensory 
R28 cells in culture (data collected from Dr. Dolores J. Takemoto and Satyabrata Das). 
R28 cells were grown in 6-well plates with coverslips. When cells reached 90% 
confluency, gap junction dye transfer activity was performed as described in Materials 
and methods. (A) The transfer of Lucifer yellow dye in the control and PQ1 treated 
cells. (B) Bar graph of percentage dye transfer in R28 cells after treatment with the 
different PQs and Mefloquine (MQ). Application of PQ1 significantly (*) inhibited 
gap junction activity. 
 
1.4.9 Effect of PQ1 on Protection against Apoptosis 
The Lucifer yellow dye transfer experiment indicated that PQ1 can inhibit the 
GJIC activities on R28 cells. Would the inhibition of GJIC prevent the apoptosis 
passing from the damaged cells to the adjacent normal cells?   
PQ1 was further tested for the protection against apoptosis induced by the 
treatment of cobalt dichloride. In this experiment, R28 cells were treated with differing 
dosages of PQ1 and CoCl2. Caspase-3 was examined to indicate the level of apoptosis. 
Without pre-treatment of PQ1, CoCl2 at 500 µM can activate caspase-3 which 
indicated the activation57, 58 of apoptosis. However, pre-incubation of R28 with PQ1 at 
10 µM for 40 minutes can block the activation significantly. CoCl2 also caused 
stabilization of HIF1a that confirmed induction hypoxia. Treatment with PQ1 alone 
did not cause activation of caspase 3 or stabilization of HIF1a respectively. PQ1, 
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CoCl2 or a combination of both did not cause any change in the Cx43 gap junction 
protein levels or phosphorylation, which indicated the PQ1 did not cause the 
down-regulation of gap junctions.  
The result from the apoptosis assay shown in Figure 10 demonstrated that 
pre-treatment of R28 cells with 10 µM PQ1 for 40 minutes can protect the cells 
significantly form undergoing apoptosis induced by CoCl2 (Figure 10A), while the 
treatment of PQ1 alone did not cause serious damage to the cells, even after 36 hours.  
 
 
Figure 10 Apoptotis assay using the Annexin V-FITC Kit (data collected from Dr. 
Dolores J. Takemoto and Satyabrata Das). (A) Representative flow cytometer images 
of R28 cells with different treatments of PQ1 and/or CoCl2. The y-axis quantifies the 
number of cells stained with propidium iodine and the x-axis quantifies number of 
cells stained with Annexin V-FITC. (B,C) Histogram of % apoptotic cells after 
treatment with CoCl2 and PQ1. The percentage of apoptotic cells represents cells that 
are Annexin V-FITC positive and both propidium iodide and Annexin V-FITC 
positive after different time periods. 
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1.5 Conclusion 
PQ1 was synthesized employing a tandem Michael addition followed by an 
electrophilic aromatic substitution reaction of substituted aniline with vinyl methyl 
ketone, reduction of the nitro function, and alkylation of the resulting amine moiety. Its 
analogs were synthesized through a reductive amination of intermidate 16 with a 
variety of aldehydes. 
PQ1 can specifically enhance GJIC activity of T47D cells without affecting the 
normal MECs. The PQ1 induced apoptosis can spread throughout the gap juctions and 
consequently cause a decrease in cell viability and colony growth. As the first known 
compound to enhance GJIC activity in T47D cells, PQ1 can attenuate tumor growth of 
xenograft tumors in Nu/Nu mice.  
Compound 7 (code PQ11) which has an IC50 of 15.6 nM against T47D cancer cells, 
is a promising candidate for further pharmacological studies.  
Interestingly, higher concentrations of PQ1 test on normal retinal R28 cells can 
significantly block the gap junction and prevent the spread of damage.  
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1.7 Experimental Section 
General procedure:  Nuclear magnetic resonance spectra were obtained at 400 MHz 
and 200MHz for 1H and 100 MHz and 50 MHz for 13C in deuteriochloroform, unless 
otherwise indicated.  Infrared spectra are reported in wavenumbers (cm-1).  
High-resolution Mass spectra were obtained from Maldi and ESI spectrometers.  
Maldi spectra were taken using 2,5-dihydroxybenzoic acid as a matrix.  ESI spectra 
were acquired on a LCT Premier (Waters Corp., Milford MA) time of flight mass 
spectrometer.  The instrument was operated at 10,000 resolution (W mode) with 
dynamic range enhancement that attenuates large intensity signals.  The cone voltage 
was 60eV.  Spectra were acquired at 16666 Hz pusher frequency covering the mass 
range 100 to 1200 u and accumulating data for 2 seconds per cycle.  Mass correction 
for exact mass determinations was made automatically with the lock mass feature in 
the MassLynx data system.  A reference compound in an auxiliary sprayer is sampled 
every third cycle by toggling a “shutter” between the analysis and reference needles.  
The reference mass is used for a linear mass correction of the analytical cycles.  
Samples are presented in Methanol plus 0.1% formic acid as a 20ul loop injection 
using an auto injector (LC PAL, CTC Analytics AG, Zwingen, Switzerland).  
4-Acetaminoanisole, vinyl methyl ketone, 3-(trifluoromethyl)phenol, and arsenic acid 
were obtained from Aldrich Chemical Co.  4-Hydroxymethylimidazole, 
thiophene-2-carboxaldehyde and 2-furaldehyde were purchased from Acros.  
Potassium t-butoxide was prepared by treating t-butanol with potassium metal at 85oC 
followed by evaporating excess of t-butanol under vacuum.  2-Bromo-4-acetamino 
anisole (9) and 2-bromo-4-acetamino-5-nitroanisole (10) were prepared by following 
the reported procedures.19 
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N-(4-methoxyphenyl)acetamide(8) 
MeO
NHCOCH3
8
 
To a solution of 5 g (40.6mmol) of p-anisidine in 50 ml of water, 5.2 g (50.75 mmol) 
of acetic anhydride was added at 80 oC. The mixture was stirred at 80 oC for 20 min, 
then cooled down to room temperature and stirred for additional 1 hour. Crude product 
precipitated out as a white solid. The solid was filtered and washed with water, dried 
under vacuum to give 5.4 g (80.5%) of compound 8: 1H NMR (CDCl3, 200MHz) 
δ 2.15 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 6.84 (d, J=8.8Hz, 2H), 7.37 (d, J=9.1Hz, 2H); 
13C NMR δ 24.17, 55.52, 114.10 (2C), 122.25 (2C), 131.34, 156.43, 169.06. 
 
2-Bromo-4-acetaminoanisole (9) 
 
MeO
NHCOCH3
9
Br
 
 
To a solution of 10 g (60.5 mmol) of N-(4-methoxyphenyl)acetamide (8) in 50 ml of 
glacial acetic acid, 11.6 g (72.7 mmol) of bromine was added slowly. Temperature was 
maintained below 50 oC while adding. The mixture was stirred at room temperature for 
1 hour, poured into 400 ml of ice water with 1.2 g of sodium bisulfite, stirred until 
color discharged. The precipitated solid was filtered out and recrystallized from 25% 
ethanol in water to give 10.19 g (69%) of compound 9: 1H NMR (CDCl3, 200MHz) 
δ 2.16 (s, 3H, CH3), 3.87 (s, 3H, OMe), 6.83 (d, J=8.8Hz, 1H), 7.41 (d-d, J=2.5Hz, 1H), 
7.67 (d, J=2.6Hz, 1H); 13C NMR δ 24.11, 56.48, 111.25, 111.94, 121.05, 125.95, 
132.02, 152.72, 169.47. 
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2-bromo-4-acetamino-5-nitroanisole (10) 
MeO
NHCOCH3
10
Br
NO2
 
To a solution of 12.3 g (50.4 mmol) of 2-Bromo-4-acetaminoanisole (9) in 20 ml of 
acetic anhydride and 40 ml of acetic acid at 5 oC, 3.51 ml (54 mmol) of concentrated 
nitric acid was added dropwise while maintaining the temperature below 5 oC.  The 
mixture was stirred at 5 oC for 3 hours, poured into 200 ml of ice water. The yellow 
precipitate was filtered out and washed with cold water, dried under vacuum to give 12 
g (82.3%) of compound 10: 1H NMR(CDCl3, 200MHz) δ 2.28 (s, 3H, CH3), 3.95 (s, 
3H, OCH3), 7.67 (s, 1H), 9.09 (s, 1H). 
 
Potassium 3-(trifluoromethyl)phenoxide(11) 
 
KO CF3
11
 
  A mixture of 1.94 g (12 mmol) of 3-(trifluoromethyl) phenol and 1.344 g (12 mmol) 
of potassium t-butoxide was stirred at room temperature under argon for 30 min.  A 
solution was resulted, and the by-product, t-butanol, was removed under vacuum and 
heat to give 2.40 g (100% yield) of 11 as a brown oil. 
 
4-Acetamino-5-nitro-2-(3-trifluoromethylphenyloxy) anisole (12).   
MeO
NHCOCH3
12
O
NO2
CF3
 
To 2.4 g (12 mmol) of compound 11 under argon, was added a solution of 3.0 g (10.4 
mmol) of bromide 10 in 20 mL of DMF via cannula.  The resulting solution was 
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stirred at 120 oC for 1 day.  Thin layer chromatography indicated the reaction was not 
completed. The reaction solution was cooled to 25 oC and an additional of 2 mmol of 
11 was added.  The solution was stirred at 120 oC for additional 12 hours, then poured 
into 200 mL of ice water, and the solid was collected by filtration, washed with water, 
dried under vacuum, and crystallized from ethanol twice to give 3.04 g (79% yield) of 
compound 12 as a yellow solid.20  1H NMR(CDCl3, 200MHz) δ 10.4 (s, 1 H, NH), 
8.39 (s, 1 H), 7.83 (s, 1 H), 7.5 (m, 2 H), 7.3 (m, 2 H), 3.93 (s, 3 H, OMe), 2.23 (s, 3 H, 
CH3); 13C NMR δ 186.2, 155.7, 153.9, 142.4, 141.5, 133.0 (q, J = 30 Hz, C-CF3), 
130.9, 125.1 (q, J = 260 Hz, CF3), 123.0, 121.7, 116.8, 116.7, 108.7, 106.6, 56.7, 21.8. 
 
4-Amino-5-nitro-2-(3-trifluoromethylphenyloxy) anisole (13).  
MeO
NH2
13
O
NO2
CF3
 
To a solution of 2.0 g (5.3 mmol) of compound 12 in 30 mL of ethanol under argon 
was added 4 mL of concentrate HCl. The reaction was heated up to reflux for 2 hours. 
The color turned from yellow to red. The solution was cooled to room temperature, 
poured into 200 mL of ice and water. The precipitate was collected by filtration, then 
washed with water twice and crystallized from ethanol to give 1.69 g (95% yield) of 13 
as an orange solid.20  1H NMR(CDCl3, 200MHz) δ 7.70 (s, 1 H), 7.5 (m, 2 H), 7.32 (m, 
1 H), 7.20 (m, 2 H), 6.15 (s, 1 H), 3.87 (s, 3 H, OMe); 13C NMR δ 155.6, 153.9, 142.3, 
141.6, 132.8 (q, J = 33 Hz, C-CF3), 130.9, 127.1, 123.7 (q, J = 272 Hz, CF3), 123.1, 
121.8, 116.8, 108.5, 106.5, 56.6. 
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6-Methoxy-4-methyl-8-nitro-5-(3-trifluoromethylphenyloxy)quinoline (14) and 
4-{N-[4-methoxy-2-nitro-5-(trifluoromethylphenyloxy)] phenylamino}2-butanone 
(15).   
14
MeO
N
O
NO2
F3C Me
MeO
N
H
O
NO2
F3C
O
15
 
To a mixture of 2.0 g (6.0 mmol) of compound 13 and 1.7 g (12 mmol) of H3AsO4, 
was added 15 mL of 85% H3PO4.  The mixture was stirred and heated to 100 oC, and 
0.7 mL (9.0 mmol) of vinyl methyl ketone was added dropwise via a syringe. The solid 
compound 13 dissolved and a dark red solution was resulted. After stirring at 100 oC 
for 20 min, the reaction solution was cooled to room temperature, poured into 200 ml 
ice and water. The pH was adjusted to 10 by 6 M NaOH solution, and the solid 
precipitate was extracted by dichloromethane three times. The combined extract was 
washed with brine, dried (MgSO4), and concentrated to give a red crude product.  The 
combined material was column chromatographed on silica gel using a gradient mixture 
of hexane, diethyl ether, and dichloromethane as eluants to give 0.58 g (25% yield) of 
quinoline 14, 1.21 g (50% yield) of compound 15, and 0.50 g (25% recovery) of 13.   
Compound 14:  1H NMR (CDCl3, 400MHz) δ 8.78 (d, J = 4 Hz, 1 H), 7.88 (s, 1 H), 
7.40 (m, 2 H), 7.27 (m, 1 H), 7.11 (s, 1 H), 6.93 (d, J = 7 Hz, 1 H), 3.87 (s, 3 H, OMe), 
2.74 (s, 3 H, Me); 13C NMR (CDCl3, 400MHz) δ 158.0, 151.0, 148.3, 146.9, 143.8, 
139.9, 136.3, 132.6 (q, J = 30 Hz, C-CF3), 130.6, 126.5, 126.0, 123.2 (q, J = 270 Hz, 
CF3), 119.5, 118.3, 112.5, 111.8, 57.3, 23.4. 
Compound 15:  1H NMR (CDCl3, 400MHz) δ 8.18 (s, 1 H), 7.78 (s, 1 H), 7.50 (m, 2 
H), 7.30 (m, 2 H), 6.32 (s, 1 H), 3.87 (s, 3 H, OMe), 3.40 (t, J = 7 Hz, 2 H), 2.75 (t, J = 
7 Hz, 2 H), 2.17 (s, 3 H, Me).  13C NMR (CDCl3, 400MHz) δ 206.1, 156.2, 153.8, 
142.5, 141.6, 132.5 (q, J = 30 Hz, C-CF3), 130.8, 127.2, 123.7 (q, J = 280 Hz, CF3), 
122.2, 121.2, 115.9, 109.8, 103.0, 56.6, 42.5, 37.7, 30.4.  Anal. Calcd for 
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C18H17F3N2O5: C, 54.27; H, 4.30.  Found: C, 54.02; H, 4.53. 
 
Cyclization of compound 15 to quinoline 14.   
14
MeO
N
O
NO2
F3C Me
MeO
N
H
O
NO2
F3C
O
15
 
To a hot (100 oC) solution of 0.11 g (0.75 mmol) of H3AsO4 in 1 mL of 85% H3PO4, 
was added 0.15 g (0.38 mmol) of ketone 15. The mixture was stirred at 100 oC for 20 
min., cooled to room temperature, diluted with aqueous NH4OH and NaOH to pH ~12, 
and extracted with ethyl acetate three times.  The organic layer was washed with 
water and brine, dried (MgSO4), concentrated, and column chromatographed on silica 
gel using a gradient mixture of hexane, dichloromethane, and diethyl ether as eluants 
to give 33 mg (23% yield) of 14, 57 mg (46% yield) of 13, and 35 mg (23% recovery) 
of 15.  
 
8-Amino-6-methoxy-4-methyl-5-(3-trifluoromethylphenyloxy) quinoline (16). 
16
MeO
N
O
NH2
F3C Me
 
To a solution of 1 g (2.65 mmol) of 14 in 0.5 mL of acetic acid and 10 mL of water, 
0.95 g (17.0 mmol) of iron was added at room temperature. The mixture was stirred at 
100oC for 2 h, cooled to room temperature, and extracted with dichoromethane three 
times.  The combined extract was washed with aqueous NaHCO3, and brine, dried 
(MgSO4), concentrated, and column chromatographed on silica gel using a gradient 
mixture of hexane, dichloromethane, and diethyl ether as eluents to give 0.78 g (85% 
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yield) of 16.22  1H NMR (CDCl3, 400MHz)δ 8.46 (d, J = 4 Hz, 1 H), 7.34 (t, J = 8 Hz, 
1 H), 7.22 (d, J = 8 Hz, 1 H), 7.15 (m, 2 H), 6.93 (d, J = 8 Hz, 1 H), 6.79 (s, 1 H), 5.15 
(bs, 2 H, NH2), 3.80 (s, 3 H, OMe), 2.63 (s, 3 H, Me);  13C NMR (CDCl3, 400MHz) δ 
159.7, 150.5, 145.6, 143.7, 142.8, 141.5, 137.7, 134.0, 132.0 (q, J = 30 Hz, C-CF3), 
130.2, 125.1, 124.6, 123.1 (q, J = 270 Hz, CF3), 118.3, 112.1, 97.9, 56.6, 23.3. 
 
6-Methoxy-8-(3-phthalimidopropylamino)-4-methyl-5-(3-trifluoromethylphenylo
xy)-quinoline (18).   
18
MeO
N
O
HN
F3C Me
N
O
O
 
A solution of 1.0 g (2.86 mmol) of 16, 0.9 g (2.9 mmol) of 3-iodopropylphthalimide 
(17) and 0.22 g (2.6 mmol) of NaHCO3 in 10 mL of DMF was stirred under argon at 
80oC for 48 h.  The reaction mixture was cooled to 25oC, diluted with 100 mL of 
water, and extracted four times with ethyl acetate.  The combined extract was washed 
with brine, dried (MgSO4), concentrated, and column chromatographed on silica gel 
using a gradient mixture of ethyl acetate and methanol as eluants to give 0.37 g (72% 
yield based on reacted 16) of compound 18 and 0.69 g (77% recovery) of 16.  
Compound 18: 1H NMR (CDCl3, 400MHz) δ 8.37 (d, J = 4 Hz, 1 H), 7.85 (m, 2 H), 
7.73 (m, 2 H), 7.34 (t, J = 7 Hz, 1 H), 7.23 (d, J = 7 Hz, 1 H), 7.05 (m, 2 H), 6.92 (d, J = 
7 Hz, 1 H), 6.54 (bs, 1 H, NH), 6.45 (s, 1 H), 3.92 (t, J = 7 Hz, 2 H), 3.82 (s, 3 H, OMe), 
3.44 (q, J = 7 Hz, 2 H), 2.60 (s, 3 H, Me), 2.20 (pent, J = 7 Hz, 2 H); 13C NMR (CDCl3, 
400MHz) δ 168.7, 159.9, 151.0, 145.0, 144.4, 142.6, 134.4, 134.2, 133.9, 132.3, 130.2 
(q, J = 30 Hz, C-CF3), 125.8, 125.2, 124.1 (q, J = 260 Hz, CF3), 123.5, 123.3, 118.3, 
118.1, 112.3, 92.9, 56.8, 41.2, 36.2, 28.2, 23.3.  Anal. Calcd for C29H24F3N3O4: C, 
65.04; H, 4.52.  Found: C, 64.95; H, 4.71.  
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6-Methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)q
uinoline (1).   
MeO
N
O
HN
F3C Me
NH2
1
 
A solution of 0.35 g (0.65 mmol) of phthalimide 18 in 10 mL of 65% hydrazine and 
10 mL of ethanol was refluxed under argon for 3 hours.  After cooling the solution to 
25oC, it was diluted with 10% aqueous KOH solution and extracted with 
dichloromethane three times.  The combined extract was washed with brine, dried 
(K2CO3), concentrated, and column chromatographed on silica gel using a gradient 
mixture of dichloromethane and methanol as eluants to give 0.21 g (80% yield) of 1  
1H NMR (CDCl3, 400MHz) δ 8.40 (d, J = 4 Hz, 1 H), 7.34 (t, J = 8 Hz, 1 H), 7.21 (d, J 
= 8 Hz, 1 H), 7.06 (m, 2 H), 6.93 (d, J = 8 Hz, 1 H), 6.48 (s, 1 H), 6.4 (bs, 1 H, NH), 
3.83 (s, 3 H, OMe), 3.42 (t, J = 8 Hz, 2 H), 2.99 (t, J = 8 Hz, 2 H), 2.62 (s, 3 H, Me), 
1.98 (pent, J = 8 Hz, 2 H), 1.80 (bs, 2 H, NH2); 13C NMR (CDCl3, 400MHz) δ 160.0, 
151.1, 145.0, 143.5, 142.7, 132.2 (q, J = 30 Hz, C-CF3), 130.2, 125.2, 123.1 (q, J = 270 
Hz, CF3), 118.4, 118.2, 112.2, 107.5, 92.9, 56.8, 41.6, 40.4, 33.1, 23.4.  Anal. Calcd 
for C21H22F3N3O2: C, 62.21; H, 5.47.  Found: C, 62.07; H, 5.62.  The succinic acid 
salt was prepared by treating 0.457 g (1.12 mmol) of the quinoline with 0.134 g (1.13 
mmol) of succinic acid in 5 ml of methanol.  The resulting solution was diluted with 
50 ml of  water and lyophilized to give a quantitative yield of the succinic acid salt of 
1. 
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6-Methoxy-8-[(2-cyanoethyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)qui
noline (2).   
MeO
N
O
HN
F3C Me
CN
2
 
A solution of 0.57 g (1.6 mmol) of amine 16 and 86 mg (1.6 mmol) of acrylonitrile in 
2 mL of phenol was heated in a sealed tube at 100oC for 2 days.  The mixture was 
cooled to 25oC, diluted with dichloromethane, washed with 1 N NaOH, water, and 
brine, dried (MgSO4), concentrated and column chromatographed on silica gel using a 
mixture of hexane:CH2Cl2:diethyl ether (4:4:1) to give 0.20 g (50% yield) of 
compound 2 and 0.11 g (20% recovery) of 16.  Compound 2:  1H NMR (CDCl3, 
400MHz) δ 8.43 (d, J = 4 Hz, 1 H), 7.36 (t, J = 8 Hz, 1 H), 7.23 (d, J = 8 Hz, 1 H), 7.08 
(m, 2 H), 6.94 (d, J = 8 Hz, 1 H), 6.71 (t, J = 7 Hz, 1 H), 6.52 (s, 1 H, NH), 3.85 (s, 3 H, 
OMe), 3.78 (q, J = 7 Hz, 2 H), 2.82 (t, J = 7 Hz, 2 H), 2.63 (s, 3 H, Me); 13C NMR 
(CDCl3, 400MHz) δ 159.7, 150.8, 145.5, 143.1, 143.0, 134.0 132.3 (q, J = 30 Hz, 
C-CF3), 132.0, 131.7, 130.3, 127.0, 125.5, 124.7, 122.9 (q, J = 270 Hz, CF3), 118.3, 
112.2, 93.6, 57.1, 39.8, 23.3, 18.4; HRMS calcd for C21H19F3N3O2 (M+H+) 402.1429, 
found 402.1422. 
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Ethyl 3-{8-[6-Methoxy-4-methyl-5-(3-trifluoromethylphenyloxy) 
quinolinyl]amino}-propanoimidate (3). 
MeO
N
O
HN
F3C Me
NH
O
3
 
To a cold (0oC) solution of 0.16 g (0.41 mmol) of cyanide 2 in 3 mL of ethanol and 3 
mL of benzene, hydrogen chloride gas was introduced for 5 min.  The gas inlet was 
removed and the reaction vessel was sealed and stirred at 25oC for 3 days.  The 
solvent was removed under vacuum and the crude product was column 
chromatographed using a mixture of hexane:CH2Cl2:diethyl ether (4:4:1) as an eluant 
to give 0.12 g (69% yield) of compound 3:  1H NMR (CDCl3, 400MHz) δ 8.41 (d, J = 
4 Hz, 1 H), 7.34 (t, J = 8 Hz, 1 H), 7.22 (d, J = 8 Hz, 1 H), 7.08 (m, 2 H), 6.93 (d, J = 8 
Hz, 1 H), 6.59 (bs, 1 H, NH), 6.54 (s, 1 H), 4.20 (q, J = 7 Hz, 2 H), 3.84 (s, 3 H, OMe), 
3.69 (t, J = 7 Hz, 2 H), 2.80 (t, J = 7 Hz, 2 H), 2.62 (s, 3 H, Me), 1.29 (t, J = 7 Hz, 3 H); 
13C NMR (CDCl3, 400MHz) δ 172.3, 159.9, 151.0, 145.5, 145.1, 144.2, 142.8, 134.0, 
132.0 (q, J = 30 Hz, C-CF3), 130.2, 126.1, 125.3, 124.6, 124.0 (q, J = 270 Hz, CF3), 
118.4, 112.3, 93.3, 61.0, 56.9, 39.4, 34.4, 23.3, 14.4; HRMS calcd for C23H26F3N3O3 
(M+2+) 449.1926, found 449.1687.  Anal. Calcd for C23H24F3N3O3: C, 61.74; H, 5.41.  
Found: C, 61.65; H, 5.49. 
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Ethyl 3-{8-[6-Methoxy-4-methyl-5-(3-trifluoromethylphenyloxy) 
quinolinyl]amino}-propionamidine (4). 
MeO
N
O
HN
F3C Me
NH
NH2
4
 
To a solution of 40 mg (0.09 mmol) of imidate 3 in 2 mL of ethanol, ammonia gas was 
introduced for 5 min.  The reaction vessel was sealed and stirred at 50oC for 6 h.  
After removal of ethanol, the crude product was column chromatographed on silica gel 
using a gradient mixture of hexane, dichloromethane, diethyl ether and methanol as 
eluants to give 21 mg (57% yield) of amidine 4 and 5 mg (13% recovery) of imidate 3.  
Compound 4: 1H NMR (CDCl3, 400MHz) δ 8.41 (d, J = 4 Hz, 1 H), 7.35 (t, J = 8 Hz, 1 
H), 7.23 (d, J = 8 Hz, 1 H), 7.08 (m, 2 H), 6.94 (d, J = 8 Hz, 1 H), 6.60 (s, 1 H), 6.55 (bs, 
1 H), 5.69 (bs, 1 H, NH), 5.40 (bs, 1 H, NH), 3.84 (s, 3 H, OMe), 3.73 (q, J = 7 Hz, 2 
H), 2.72 (t, J = 7 Hz, 2 H), 2.62 (s, 3 H, Me); 13C NMR (CDCl3, 400MHz) δ 173.6, 
159.8, 151.0, 145.2, 144.2, 142.9, 134.0, 131.8 (q, J = 30 Hz, C-CF3), 130.2, 126.3, 
125.7, 125.3, 124.6, 124.5 (q, J = 270 Hz, CF3), 118.4, 112.2, 93.7, 56.9, 39.8, 30.5, 
23.4; Anal. Calcd for C21H21F3N4O2: C, 60.28; H, 5.06.  Found: C, 61.01; H, 5.27. 
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6-Methoxy-8-[(4-imidazolylmethyl)amino]-4-methyl-5-(3-trifluoromethylphenylo
xy)-quinoline (5). 
MeO
N
O
HN
F3C Me
N
N
H5
 
The following procedure serves as a general procedure for the reductive amination 
reaction. 
A solution of 0.18 g (0.51 mmol) of quinoline 16 and 55 mg (0.57 mmol) of 
aldehyde 928 in 5 mL of methanol was stirred at 25oC under argon for 1 h.  To it, 10 
mg of acetic acid was added, and the solution was stirred for 1 h, and 96 mg (1.5 mmol) 
of sodium cyanoborohydride was added.  After stirring for 3 h, the solution was 
diluted with aqueous NH4Cl and extracted with dichloromethane twice.  The 
combined extract was washed with brine, dried (MgSO4), concentrated, and column 
chromatographed using a gradient mixture of hexane, ethyl acetate, and methanol as 
eluants to give 0.18 g (79% yield) of compound 1.5 and 14 mg (8% recovery) of 
compound 16.  Compound 5: 1H NMR (CDCl3, 400MHz) δ 8.41 (d, J = 4 Hz, 1 H), 
7.66 (s, 1 H), 7.33 (t, J = 8 Hz, 1 H), 7.22 (d, J = 8 Hz, 1 H), 7.08 (m, 3 H), 6.92 (d, J = 
8 Hz, 1 H), 6.78 (bs, 1 H, NH), 6.60 (s, 1 H), 4.60 (s, 2 H), 3.78 (s, 3 H, OMe), 2.62 (s, 
3 H, Me); 13C NMR (CDCl3, 400MHz) δ 159.9, 151.0, 145.1, 144.4, 142.8, 135.2, 
134.0, 132.3 (q, J = 30 Hz, C-CF3), 130.2, 126.2, 125.2, 124.5, 124.2 (q, J = 270 Hz, 
CF3), 118.2, 116.3, 112.3, 95.3, 93.9, 56.8, 41.5, 23.3; HRMS calcd for C22H20F3N4O2 
(M+H+) 429.1538, found 429.1521. 
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6-Methoxy-8-[(2-thiophenylmethyl)amino]-4-methyl-5-(3-trifluoromethylphenylo
xy)-quinoline (6). 
MeO
N
O
HN
F3C Me
S6
 
   A similar procedure as that described above was carried out using 0.12 g (0.34 
mmol) of quinoline 16 and 42 mg (0.38 mmol) of 2-thiophenecarboxaldehyde to give 
72 mg (47% yield) of quinoline 6 and 43 mg (36% recovery) of starting material 16 
after column chromatographic purification.  Compound 6: 1H NMR (CDCl3, 400MHz) 
δ 8.41 (d, J = 4 Hz, 1 H), 7.33 (t, J = 8 Hz, 1 H), 7.21 (m, 2 H), 7.09 (m, 3 H), 6.99 (d, J 
= 8 Hz, 1 H), 6.92 (d, J = 8 Hz, 1 H), 6.85 (bs, 1 H, NH), 6.58 (s, 1 H), 4.75 (s, 2 H), 
3.77 (s, 3 H, OMe), 2.62 (s, 3 H, Me); 13C NMR (CDCl3, 400MHz) δ 159.8,  150.9, 
145.2, 144.0, 142.9, 142.6, 134.0, 132.3 (q, J = 30 Hz, C-CF3), 130.2, 127.1, 126.4, 
125.5, 125.2, 124.9, 124.5, 124.2 (q, J = 280 Hz, CF3), 118.3, 118.2, 112.3, 94.0, 56.7, 
43.3, 23.3; HRMS calcd for C23H20F3N2O2S (M+H+) 445.1197, found 445.1183. 
 
6-Methoxy-8-[(2-furanylmethyl)amino]-4-methyl-5-(3-trifluoromethylphenyloxy)
-quinoline (7). 
MeO
N
O
HN
F3C Me
O7
 
 
A similar procedure as that described above was carried out using 0.17 g (0.47 mmol) 
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of quinoline 16 and 50 mg (0.52 mmol) of 2-furancarboxaldehyde to give 0.11 g (52% 
yield) of quinoline 7 and 20 mg (12% recovery) of starting material 16 after column 
chromatographic purification.  Compound 7: 1H NMR (CDCl3, 400MHz) δ 8.41 (d, J 
= 4 Hz, 1 H), 7.41 (s, 1 H), 7.33 (t, J = 8 Hz, 1 H), 7.21 (d, J = 8 Hz, 1 H), 7.09 (m, 2 H), 
6.92 (d, J = 8 Hz, 1 H), 6.76 (bt, J = 5 Hz, 1 H, NH), 6.60 (s, 1 H), 6.35 (m, 2 H), 4.56 
(d, J = 5 Hz, 2 H), 3.80 (s, 3 H, OMe), 2.62 (s, 3 H, Me); 13C NMR (CDCl3, 400MHz) 
δ 159.9, 152.5, 150.9, 145.2, 144.1, 142.8, 142.3, 134.1, 132.2 (q, J = 30 Hz, C-CF3), 
130.2, 126.4, 125.2, 124.5, 124.1 (q, J = 280 Hz, CF3), 118.4, 118.2, 112.3, 110.6, 
107.5, 93.8, 56.8, 41.3, 23.3; HRMS calcd for C23H20F3N2O3 (M+H+) 429.1426, found 
429.1532.  
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CHAPTER 2-Synthesis and Bioactivities of Nanogels 
 
2.1 Introduction 
  In the current field of medical research, one problem that need to be addressed is the 
discovery of a proper drug carrier.1-2 Most of the drugs are small organic compounds 
that are not soluble in aqueous media. Since the development of nanotechnology, 
nanopaticles have been widely studied as one of the possible systems that can control 
the release of many small molecules.3-6 Micelles,7 immunoliposomes,8 liposomes,9,10 
lipoplexes,11 and cell-pentrating peptiedes12 have been reported for the 
intra-cytoplasmic drug delivery. Polymeric nanogels based on Poly Ethylene Glycol 
(PEG) has more recently emerged as a promising system for the drug delivery5, 13-15 
due to the biocompatibility and high solubility in aqueous media. Poly Ethylene imine 
(PEI) combined with PEG has been reported to be utilized as a nonviral gene delivery 
material. The PEI can be crosslinked with PEG to form a more stable nanogel which is 
water soluble and less toxic6, 16-18 compared to PEI alone.13, 17-20  
Specification is currently another problem in the realms of drug delivery. The 
delivery of the drug directly into the tumor to reduce the dosage and minimize the side 
effects of the drugs is currently a challenging endeavor. Recently, research on stem 
cells demonstrated that umbilical cord matrix stem cells (UCMS) can engraft near or 
even within the tumors when administered to tumor-bearing mice.21 This indicated that 
UCMS may severe as a potential delivery vehicles to carry and release the nanogels 
into tumors  
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Figure 11 Dye-loaded UCMS cells (red cells) were detected in small breast tumor 
(green) but not in the surrounding normal lung tissue (blue).  
 
In this study, we synthesized three types of nanogels and encapsulated them with 
different anticancer drugs. These nanogels were internalized into the stem cells and 
subsequently evaluated to determing their abilities in releasing drugs to the cancer cells. 
All the bioactivities were evaluated by Dr. Chanran Ganta and Dr. Rajashekar 
Rachakatla in Dr. Deryl Troyer’s lab. 
 
2.2 Tpye I Nanogel 
  The PEI bought from Aldrich was purified by a Sephacryl S200 chromatograph 
column to obtain PEI with a much more uniformed molecular weight.6 The medium 
fractions were collected and used for the synthesis of nanogel. 
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2.2.1 Synthesis of Toxic PEG-PEI Nanogel 
  Initially, the nanogel was prepared by following the reported procedure6 with a few 
modifications. Poly ethylene glycol (PEG) has been widely utilized in recent cancer 
research due to its water solubility and bio-compatibility. PEG can also be 
functionalized on the hydroxyl groups. The activation of PEG was achieved by 
treatment with 1, 1’-carbonyldiimidazole in distilled dry acetonitrile at 40oC for 2 
hours. The resulting light yellow solution was dialyzed twice with 800 ml of 10% 
ethanol in deionized water at 4 oC for 4 hours using a membrane with a molecular 
weight cut off (MWCO) of 3500 Dalton. It is very crucial to keep the temperature low 
at 4 oC since higher temperature would result in the hydrolysis of the activated PEG. 
The desired product was lyophilized immediately to give a white solid.  
  To make the nanogel, 1 g of purified PEI (MW around 25 KDa) was dissolved in 300 
ml deionized water, and a solution of 1 g of activated PEG in 5 ml dichloromethane 
was then added drop wise to the PEI solution at room temperature. A white suspension 
was resulted due to the heterogeneous solvent system which was sonicated for 15 
minutes. The organic solvent dichloromethane was removed on a rotary evaporator to 
afford a transparent solution which was subsequently dialyzed with 1000 ml 10% 
ethanol in deionized water at room temperature using a membrane with molecular 
weight cut off (MWCO) of 12 KDa-14 KDa. Since the activated PEG was around 8 
KDa, the activated PEG was successfully separated from the nanogel. Lyophlization of 
the resulting solution afforded the desired nanogel as a white light powder.  
  Based on the method we used for the synthesis, the structure of the nanogel was 
tenatively proposed and is shown in Scheme 7. This proposed structure has not yet 
been confirmed.  
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Scheme 7 Synthesis of PEG-PEI Nanogel (26)
 
    
As a drug carrier, the nanogel should be nontoxic to stem cells. However, after being 
evaluated on the cell line, the naogel prepared above was toxic to the cells. The proton 
NMR spectrum of nanogel revealed a ratio of 1:4 for the CH2N:CH2O (methylene 
protons) respectively. We anticipated that the ratio of the PEG to PEI was what played 
an important role in the toxicity of the nanogel. The higher ratio of PEI in the nanogel 
would indeed result in a higher toxicity16, 18 of the nanogel since PEG is highly 
biocompatible.  
  Two strategies were investigated. One possibility is to block some of the free amino 
groups of the PEI that might have played a role to cause the toxicity of the nanogel and 
another possibility is to increase the ratio of PEG by optimizing the synthetic 
procedure. 
 
 
 
 
 - 47 - 
2.2.2 Synthesis of Acetylated Nanogel (Ac-NG) 
  Acetic anhydride was utilized to block part of the free amino groups of nanogel 26. 
Acetylation on the amino groups of 1:4 ratio nanogel 26 was achieved by treatment of 
the nanogel with acetic anhydride in acetonitrile at 50 oC for 12 hours followed by 
dialysis and lyophilization. The acetylated nanogel was evaluated against the cancer 
cells and the results indicated that this nanogel was nontoxic to the cells.  
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2.2.3 Synthesis of Nontoxic PEG-PEI Nanogel (NG) 
To increase the ratio of PEG, the sonication (after the adding of activated PEG into 
PEI solution) time was optimized. Instead of 15 minutes, the nanogel was sonicated for 
30 minutes or 60 minutes, and the results showed that the ratio of CH2N:CH2O 
(methylene protons) remained unchanged 1:4 in the proton NMR spectrum. The same 
result was obtained when the volume of deionized water was reduced from 300 ml to 
200 ml. This indicated that an increase of sonication time or an increase in 
concentration does not affect the PEI: PEG ratio. When double the amount of activated 
PEG was used, the composition of the resulting nanogel still remained unchanged, as a 
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1:4 ratio of the CH2N :CH2O (methylene protons) was again observed.  
  The toxic nanogel (1.16 g) was further treated again with 1g of activated PEG 
following the same procedure to afford 1.32 g of a new nanogel. The results indicated 
that the CH2N:CH2O (methylene protons) ratio of the new nanogel had changed from 
1:4 to 1:6.8. When tested on the stem cells, this nanogel was nontoxic to the cells. As 
shown in Figure 12, nanogel PEI: PEG (1:4) resulted in 80% inhibition of Pan 02 cell 
growth at 0.04 mg/ml while nanogel PEI: PEG (1:6.8) still had 90% cell viability at 
even 0.1 mg/ml. Based on the optimization, one single treatment of PEI with activated 
PEG resulted in a partially cross-linked nanogel; the ratio of CH2N:CH2O was about 
1:4 which was toxic to stem cells; double treatment with activated PEG would increase 
the CH2N:CH2O ratio to 1:6.8 which was nontoxic to stem cells.  
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Figure 12 Cell viability of PAN 02 cell treated with PEI: PEG (1:4) and PEI: PEG 
(1:6.8) nanogels. Pan 02 cells were seeded in a 96 well plate and after reaching 70% 
confluency, the media was replaced with fresh medium containing nanogel PEI: PEG 
(1:4 or 1:6.8) at different concentrations and incubated for 48 hours. MTT assays were 
performed. 
 
2.2.4 Synthesis of Rhodamine Attached Nanogel (NG-Rh) 
  Since the nanogel was not florescent, it was difficult to detect whether it was 
up-taken by the stem cells or not.  Rhodamine B dye was subsequently attached to the 
nanogel as an indicator. Rhodamine B was covalently linked to the nanogel. The 
activation of the carboxylic acid group of rhodamine B was accomplished by reaction 
with Hydroxybenzotriazole (HOBt), Dicyclohexylcarbodiimide (DCC) and 
N-Hydroxysuccinimide (NHS) in DMF at 55 oC for 2.5 hours. The activated rhodamine 
dye was then treated with nanogel 28 in acetonitrile at 40 oC for 12 hours. The resulting 
pink solution was dialyzed with a 12KDa-14KDa MWCO membrane in a solution of 
10% ethanol in deionized water at 25 oC for 24 hours to remove the excess rhodamine. 
The rhodamine attached nanogel 29 was obtained as a pink powder after 
lyophilization. 
 
 - 50 - 
N
N
H
O O O
O
n NH N
O
N
N
H
O O O
O
N
H N
O
HN
NH
NH
NH
m m
N H
N O O O
O n
H
N
N
O
N H
N O O O
O
H
N N
O
HN
N
NH
N
NH
NH2
H
N N
H2N
H
N N
H2N
H
Nl
TAMRA-SE
O
Me2N
NMe2
CO
O2C Nanogel NG-Rh
 (MW ~32 KDa)
              NG
Nanogel(PEI:PEG=1:6.8)
             28
N
H
O O O
O
n NH
O
29
Scheme 10 Synthesis of Rhodamine attached Nanogel (NG-Rh)
DMF
 
 
2.2.5 Encapsulation of AQ10 into Nanogel 
An anthraquinone derivative, AQ10, has been reported22-24 to have toxicities against 
some cancer cell lines by triggering apoptosis and causing inter-nucleosomal DNA 
fragmentation. AQ10 was utilized as an anticancer drug to target at Pan 02 cancer cell 
lines. The dosage effect of AQ10 alone against Pan02 was evaluated. The results 
indicated that 2 ug/ml (9.2 µM) would reduce the cell viability to around 70% while 4 
ug/ml (18.4 µM) can further decrease it to 25%.  
O
O
AQ10
HOH2C
AQ10
 
Figure 13 Structure of AQ10 
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Figure 14 Cell viability of Pan 02 cells when treated with different dosages of AQ10. 
Pan 02 cells were seeded in a 96 well plate and after reaching 70% confluency, the 
media was replaced with fresh medium containing AQ10 or control (DMSO) at 
different concentrations and incubated for 48 hours. MTT assays were performed.  
 
AQ10 was then encapsulated into the NG synthesized as shown below in Scheme 11. 
50 mg of NG was dissolved in 5 ml of deionized water and mixed well with a solution 
of 0.5 mg AQ10 in 1 ml of acetonitrile. The resulting solution was lyophilized 
immediately to give a quantitative yield of 1% AQ10 with NG (by weight ratio) as a 
brown powder. Other drugs gave different weight ratios of encapsulation, and were 
accomplished by a similar procedure.  
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2.2.6 Loading of Nanogel (NG-Rh) to Stem Cells (UCMS) 
  Umbilical Cord Matrix Stem (UCMS) cells were used as a carrier for the nanogel 
and anticancer drugs. The incorporation of the nanogels into the stem cells was studied. 
As shown in Figure 15 and 16, UCMS cells were loaded with rhodamine attached 
nanogel 29 (NG-Rh) at different time points. The internalized NG-Rh was observed by 
a fluorescent microscope followed by imaging. As cells gained more NG-Rhs, the 
nanoparticles were distributed throughout the cytoplasm. The loading kinetics over a 
period ranging from 30 minutes to 36 hours was determined. The maximum loading of 
nanogel 29 was achieved at 24 hours, which was 5% of the total loaded nanogel.  
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Figure 15 Loading kinetics of nanogel (NG-Rh) into stem cell. Nanogel 29 loading 
into stem cells increased with time following incubation of nanogel PEG/PEI with 
UCMS cells. Nanoparticles loaded was normalized to total cellularprotein  
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Figure 16 Nanogel (NG-Rh) up taken by stem cells at different time points. The 
punctuate red fluorescence indicates rhodamine labeled nanoparticle internalized by 
the stem cells (Arrow indicates cell nucleus)  
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2.2.7 Viability of Stem Cells Loaded with AQ10-NG-Rh 
The results shown above indicated that nanogels actually internalized into the stem 
cells. Then the next question is whether the stem cells can survive during the 
transportation of nanogel to the tumor since AQ10 loaded nanogel 31 (AQ10-NG-Rh) 
is toxic to Pan 02 cancer cells. The cell viability evaluation of stem cells upon the 
treatment of AQ10-NG-Rh was subsequently performed. The results demonstrated that 
when treated with 0.1 mg/ml of nanogel 31 (AQ10-NG-Rh) for 48 hours, the stem cell 
still had a 100% viability. 
 
Figure 17 Cell viabilities of stem cells upon treatment of nanogel (AQ10-NG-Rh). 
Stem cells were treated with different concentration of nanogel (AQ10-NG-Rh) and 
incubated for 48 hours. MTT assay results are shown in panel A. The fluorescence 
images after 48 hours are shown in panel B. 
 
2.2.8 AFM Image of Nanogel (AQ10-NG) 
The size of 1% AQ10-NG was studied by Atomic Force Microscopy (AFM) using a 
tapping mode with a high aspect ration tip. Several samples were examined.  The 
images were similar, and two of them are shown in the top panel of Figure 18. The 
zoom-in images in the middle panel show the round particles with diameter of 
approximately 23 nm and height of approximately 1 nm. Some aggregations of small 
nanogels to short fibril-like materials were also observed as can be seen in the bottom 
panel.  
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Figure 18 AFM image of nanogel (AQ10-NG). Top panels: AFM images of 
AQ10-NG-Rh sample at two different locations on mica. Middle left panel: a zoom-in 
AFM image of a nanogel (AQ10-NG) particle and its width and height are shown in 
middle right panel. Bottom left panel: a zoom-in AFM image of an aggregated nanogel 
(AQ10-NG) particle and its height and width are shown in bottom right panel. 
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2.2.9 Results of AQ10-NG on Pan 02 Cells 
The AQ10 loaded nanogel 30 (AQ10-NG) was tested on the inhibition of Pan 02 
cell proliferation in a dose-dependent manner. The results showed that nanogel 28 (NG) 
had no significant inhibition effects on the Pan 02 cell proliferation as compared to the 
control. When treated with AQ10 encapsulated nanogel 30, the Pan 02 cell viability 
decreased significantly to around 60% at 0.06 mg/ml dosage and with a further 
rduction to 30% at 0.08 mg/ml dosage. Since there was only 1% of AQ10 by total 
weight of the nanogel, 0.06mg/ml of nanogel only contained 0.6 µg/ml (2.8 µM) of 
AQ10. As a comparison, when treated with AQ10 alone, 2 µg/ml (9.2 µM) AQ10 can 
only reduce the cell viability to about 70%. The results indicated that the AQ10 was 
about four times more effective when encapsulated with nanogel than alone. Due to the 
low solubility of AQ10 in water, it can not be loaded into the cells effectively; however, 
when incorporated into the nanogel which is highly soluble in water, a more efficient 
loading of AQ10 into the cells resulted, which allowed for a decrease in dosage.  
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Figure 19 Dose effects of nanogel (NG) and 1% AQ10-nanogel (AQ10-NG) on Pan 02 
cell viability. Pan 02 cells were seeded in a 96 well plate and after reaching 70% 
confluency, the media was replaced with fresh medium containing nanogel (NG or 
AQ10-NG) at different concentrations. Following incubation for 48 hours cell 
proliferation assays were performed. MTT assay results were shown in top panel and 
hemocytometer-trypan blue exclusion results were shown in the bottom panel. 
 
In summary, the synthesis of nontoxic PEG-PEI nanogel (NG) was achieved by 
double treatments of PEI with activated PEG. PEG-PEI nanogels can be loaded with 
anticancer drug (AQ10) and release the drug to kill the cancer cell Pan 02 and the drug 
dosage was significantly lower when combined with nanogel than the drug alone. 
Attached rhodamine on the nanogels can indicate the location of nanogels in the cell 
system and the rhodamine attached nanogel was internalized into the UCMS cells. 
These results suggested that the nanogel is a novel anticancer drug carrier which could 
be incorporated into stem cells. The stem cell can be used as a delivery vehicle to 
specifically release the nanogel with anticancer drugs to cancer cells.   
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2.3 Type II Nanogels 
When we carefully examine this delivery system above, there are two major 
concerns: 1. the capability of the nanogel to load with anticancer drugs; and 2) the 
internalization capability of nanogel into UCMS cells. If only a limited amount of 
anticancer drugs can be encapsulated to the nanogel, it may not be efficient enough to 
attenuate or inhibit the cancer growth. The nanogel with AQ10 above contained only 
1% (by weight) of anticancer drug. We had successfully encapsulated up to 5% (by 
weight) while higher percentages failed. This problem may not be crucial if the 
anticancer drug is sensitive. However, for some less powerful drugs, even 5% 
encapsulation would result in a higher dosage of nanogels. Nevertheless, the lower the 
capability of incorporation of nanogel into the stem cells, the larger the quantity of 
nanogels and anticancer drugs would be required. The results showed above that only 
about 5% of the total nanogels can be internalized into the stem cells. Hence, 
increasing the amount of anticancer drug in the nanogels and the incorporation 
capability of the nanogel into the stem cells would significantly improve the efficiency 
of nanogel drug delivery system.   
 
2.3.1 Background of SN38 and Legumain 
Camptothecin (CPT) is a natural product isolated25 from the bark and stem of a plant 
native to China. It has remarkable anticancer activities26 in tumor cells. CPT 
selectively binds to DNA enzyme topoisomerase I (TOP1) during the cleavage of DNA 
which then causes DNA damage and apoptosis.27 The oxygen atoms on the lactone E 
ring of CPT bind to the enzyme, and the hydroxyl group binds to aspartic acid 533 on 
the side chain of the enzyme.28 Only the S configuration of the chiral carbon is active, 
and the opening of lactone E ring would result in a loss of activity.29, 30  
However, the low solubility and substantial toxicity of camptothecin prevents its 
development and use in clinical trials.31 Several analogs have been synthesized. In 
1997, two analogs with much a higher water solubility, topotecan and irinotecan 
(CPT-11) were approved by the U.S. Food and Drug Administration as anticancer 
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agents. The most active analog so far is SN38 (7-ethyl-10-hydroxy-camptothecin) 
which is also the active metabolite of CPT-11 produced by esterase-mediated 
hydrolysis. Unfortunately, like camptothecin, SN38 has even lower water-solubility. 
Moreover, less than 10% of CPT-11 would be converted to its active ingredient SN38 
in human body system.32-34 Another limitation is that the lactone E ring of SN38 can be 
easily opened34-36 and therefore loss in the activity before reaching the tumor site. 
Hence, increasing the solubility of SN38 and preventing the ring opening reaction may 
have therapeutic benefits. Hong Zhao and his coworkers linked SN38 with poly 
ethylene glycol to stabilize the compound and increase the solubility.37 The results 
demonstrated much higher anticancer activity compared to CPT11.  
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Figure 20 Camptothecin and some of its analogs. 
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Legumain, 38-41 a gene that encodes a cysteine protease that can specifically 
hydrolyze an asparaginyl bond, 42 is highly expressed in many tumors43 due to the 
down-regulation of its inhibitors such as cystatin C.44 However, the activity of 
legumain could be inhibited by such cystheine protease inhibitors in normal tissues. 
Hence, legumain could be a potential targeting candidate45 for drug delivery. A short, 
specifically designed peptide sequence that contains one asparagine and links with an 
anticancer drug would be recognized and hydrolyzed by legumain; thus, the anticancer 
drug could be released to the tumor.  In a report  by Wenyuan Wu and her coworkers, 
38
 a prodrug using a short peptide with 4 amino acids (Ala-Ala-Asn-Leu) that is linked 
with doxorubincin was synthesized and tested. The results indicated that legumain can 
actually recognized the sequence and cut right in between asparagine and leucine to 
release doxorubincin linked with leucine, which was further converted to the end 
product doxorubincin.  
As to our nanogel system, we firstly tested the simple encapsulation with 1% and 5% 
of SN38 into the nanogel; however, even at 5% the SN38 system did not show much 
enhanced efficiency than the SN38 alone. It also turned out that higher percentage of 
SN38 can not be successfully encapsulated into nanogels. Thus, another method was 
developed by attaching the SN38 prodrug to the outside of the nanogel with a short 
peptide linker. SN38 was modified at the hydroxyl group of the lactone E ring to have a 
carboxylic acid functional group at the end that can be linked to the amino end of the 
peptide. The same sequence of peptide (Ala-Ala-Asn-Leu) was synthesized by solid 
phase peptide synthesis and then coupled with modified SN38. This prodrug was 
covalently attached to the outside of nanogel that still had free amino groups. To 
enhance the activity and increase the loading efficiency, 5% of SN38 was encapsulated 
into the prodrug nanogel. 
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2.3.2 Synthesis of SN38 linkers 
Synthesis of SN38 derivatives with a side chain linker was accomplished by 
following the literature reported method37 with some modifications. 10-OH on A ring 
was selectively protected with t-butyl-diphenylsilyl chloride and triethylamine in 
dichloromethane under reflux for overnight. Initially, the SN38 was not soluble in 
dichloromethane; the suspension was yellow after the adding of triethylamine. A 
greenish solution was formed when the reaction finished. However, the reported 
recrystallization37 using dichloromethane and petroleum ether was not efficient to 
obtain the pure product. The compound was purified by a silica gel column 
chromatography using 80:2 dichloromethane and methanol as the eluant. The yield 
was 100% as compared to 65% from the literature report.    
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Boc-Glycine was coupled with the hydroxyl group on the lactone E ring of 
compound 36 in dichloromethane using N-ethyl-N’- (3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 4-Dimethylaminopyridine (DMAP) as 
coupling reagents at 0 0C for overnight. Pure product 37 was obtained as a green solid 
after work up in a yield of 96%. The Boc-protecting group was removed in a solution 
of 2 M HCl in dioxane at room temperature for 1 hour. Compound 38 was obtained as 
a brown solid in 99% yield.  
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In order to couple SN38 derivatives to the peptide on the amino end, the amine end 
of compound 38 was converted into a carboxylic acid by reacting compound 38 with 
succinic anhydride in dioxane at 90 0C for 1 hour.  Silica gel column chromatography 
using 15:1 dichloromethane and methanol gave compound 39 as a brown solid in 96% 
yield. 
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2.3.3 Synthesis of Peptides 
The 4 amino acids peptide (Ala-Ala-Asn-Leu) was synthesized using microwave 
Fmoc solid-phase peptide synthesis. All the Fmoc protected amino acids and resins 
(Fmoc-Ala-NovaSyn TGA) were purchased from CEM. The resin was firstly 
deprotected using a solution of 20% of piperidine in DMF followed by washing with 
100 ml DMF, and coupling with Fmoc-Ala-OH using O-Benzotriazole 
N,N,N',N'-tetramethyl uronium hexafluoro phosphate (HBTU)  and Diisopropyl ethyl 
amine (DIEA) in DMF. The other two amino acids were attached respectively by 
repeating the deprotection, wash, coupling and wash cycle. After the final deprotection 
and wash, the Resin-Ala-Ala-Asn-Leu-NH2 (Resin-Peptide 41) was obtained as a 
solid.  
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wash
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wash
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2.3.4 Synthesis of Peptide-SN38 (43) 
Compound 39 was activated by HBTU and DIEA in DMF, and this mixture was then 
added to the reaction vessel that contained the resin-peptide. After coupling, the 
reaction vessel was washed with 100 ml of dichloromethane to remove any by-product 
and starting reagents while the product was attached to the solid resin. To cleave the 
Peptide-SN38 off the resin, a cleavage solution of 95% trifloroacetic acid (TFA), 2.5% 
water and 2.5% triisopropylsilane (TIS) was prepared and added to the reaction vessel 
immediately. This cleavage program was repeated twice to enhance the cleavage of the 
peptide. The Peptide-SN38 was collected by filtration; and the resin was washed with 
4 ml dichloromethane twice. After removal of the solvent, the crude Peptide-SN38 was 
further purified by HPLC equipped with a UV detector. There was only about a 20% 
yield for the final coupling and cleavage reactions as most of the materials were lost 
during the work up and HPLC purification. 
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2.3.5 Synthesis of SN38-NG-Peptide-SN38 (45) 
  The coupling of nanogel with peptide-SN38 was accomplished by using 
N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 
4-dimethylaminopyridine (DMAP) in dichloromethane. After the outside 
peptide-SN38 chain was attached to the nanogel, 5% (by weight) of SN38 was 
encapsulated into the nanogel system. Since the SN38 was UV active it could be 
tracked by confcal microscope; no rhodamine dye was attached.   
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2.3.6 Results and Discussions 
Nanogels NG-Peptide-SN38 (44) and SN38-NG-Peptide-SN38 (45) were tested on 
B-16 melanoma cancer cells. B-16 cells were chosen due to their rapid proliferation. 
As shown in Figure 21, when loaded with NG-Peptide-SN38 (44) at 0.1 mg/ml which 
contained no SN38 inside, the viabilities of B16 went down dramatically. 25% 
viability was observed on the first day and around 20% on the second day, however, it 
raised up to 60% on the third day and 100% on the forth day due to its proliferation 
ability and over expression of legumain. The results demonstrated that nanogel 44 was 
indeed toxic to cancer cells due to the outside attachment of SN38 which was probably 
cut off and released causing the toxicity. However, a higher dosage or more toxic 
nanogel that can further lower the cell viability to less than 25% on the first day was 
required.  
SN38-NG-Peptide-SN38 (45) was expected to be more powerful than 
NG-Peptide-SN38 (44) since 45 is encapsulated with 5% of SN38 inside the nanogel. 
The results shown that when treated with the same concentration of 45 (0.1mg/ml), the 
viabilities of B16 decreased to 18% on the first day as compared to 25% for 44; even 
on the forth day, the cell viabilities still remained around 10% for nanogel 45. 
SN38-NG-Peptide-SN38 (45) can inhibit the growth of B16 at a much lower dosage. 
As shown in figure 21 (bottom panel), when B16 was loaded with 45 at 0.025 mg/ml, 
the cell viability remained less than 20% even on the forth day; while for 44, cell 
viabilities all increased to around 100% again on the forth day.  
These results suggested that, without the encapsulation of SN38 inside, the SN38 
outside chain attached nanogel 44 was toxic to cancer cells, which might have been 
cleaved by legumain. The encapsulation of SN38 significantly increased the toxicity of 
nanogel which showed inhibition of B16 growth at concentrations lower than 
0.025mg/ml.  
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Figure 21 Dose effects of type II nanogels on B16 cell viability. B16 cells were seeded 
in a 96 well plate and after reaching 70% confluency, the media was replaced with 
fresh medium containing nanogel (44 or 45) at different concentrations. Following 
incubation for 96 hours cell proliferation assays were performed every 24 hours. 
Result of nanogel 44 was shown on top panel and that of nanogel 45 was shown on 
bottom panel 
 
 
 
 - 69 - 
B16 cells were treated with nanogels and legumain together. As shown in Figure 22 
(top panel), legumain itself caused no toxicity to cancer cells. When B16 cells were 
treated with nanogel 44 (no encapsulation of SN38) at 0.05mg/ml, without legumain, 
the cell viability was about 44% on the first day. When 0.1mg/ml of legumain was 
added, the cell viability decreased to about 38% on the first day. Similar effects were 
observed when nanogel 45 was tested.  
Without the addition of extra legumain, the B16 cells could still express legumain, 
which can therefore cleave the peptide and release the drug SN38, and subsequently 
cause the inhibition. However, since the media was replaced on the first day, the initial 
concentration of legumain was low. When added with extra legumain, a further down 
regulation was observed due to the higher concentration of legumain.  
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Figure 22 Dose effects of type II nanogels with legumain on B16 cell viability. B16 
cells were seeded in a 96 well plate and after reaching 70% confluency, the media was 
replaced with fresh medium containing nanogel (44 or 45) and legumain at different 
concentrations. Following incubation for 72 hours cell proliferation assays were 
performed every 24 hours. Result of nanogel 44 was shown on panel A and that of 
nanogel 45 was shown on panel B. 
 
Nanogel 45 was tested on the cell viability of neural stem cells (NSC). Since stem 
cells would serve as a carrier for the nanogels, it is required that stem cells can resist 
the toxicity of the nanogels.  The results indicated that, at a concentration of 
0.01mg/ml, the stem cells had about 50% viability on day 1 and 60% on day three 
(Figure 23), which was acceptable for the delivery of nanogels.  
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Figure 23 Dose effects of nanogel 45 on neural stem cell (NSC) viability. NSCs were 
seeded in a 96 well plate and after reaching 70% confluency, the media was replaced 
with fresh medium containing nanogel 45 at different concentrations. Following 
incubation for 72 hours cell proliferation assays were performed every 24 hours.  
 
2.4 Type III Nanogels 
2.4.1 Background 
Biotin, also called vitamin H, is essential for the production of fatty acids needed for 
the cell growth. The concentration of biotin around the tumors is significantly higher 
than that around normal cells due to the large demand of biotin for the proliferation of 
the cancer cells. The biotin receptors on the cancer cell surface are usually over 
expressed, 47 and have been explored as candidates48 for the targeting of cancer cells. 
Several approaches have been reported to enhance the drug delivery efficiency such as 
dendrimers,47 pyrenes,49 polymers,50 and nanoparticles.51  
  Streptavidin, a protein with a molecular weight of about 52800 Daltons, is known for 
its high affinity for biotin. The dissociation constant (Kd) is on the order of 10-14 mol/L, 
which makes the streptavidin-biotin bond among the strongest protein-ligand 
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interactions.52 
  To target at the cancer cell, two approaches have been investigated. The first method 
involves directly attaching the biotin onto the nanogel, which is called biotinylation. 
This biotinylated nanogel can be recognized and picked up by cancer cells. The second 
approach involves attaching streptavidin onto the nanogel, which can bind to biotins 
around the tumor and then be caught by the cancer cells. Hence, biotinylated nanogel 
and streptavidin-nanogel were synthesized. 
 
2.4.2 Synthesis of Biotinylated Nanogel 
  Biotin was activated by treatment with N,N’-dicyclohexylcarbodiimide (DCC) and 
N-hydroxysuccinimide (NHS) in DMF for 3 hours at room temperature. After filtration, 
the remaining solution (12 ml) was poured into diethyl ether (100 ml) to precipitate out 
the activated biotin. Coupling of the activated biotin with nontoxic nanogel 28 was 
accomplished by adding a solution of 100 mg nanogel in 1 ml acetonitrile into 3 mg of 
activated biotin in 1 ml of DMF followed by stirring at 50 ºC for 24 hours. Dialysis 
with 1000 ml of 10% ethanol in diionized water at room temperature for 24 hours 
using a 12kDa-14kDa molecular weight cut off membrane gave the biotinylated 
nanogel as a single product. Rhodamine dye was attached to the biotinylated nanogel 
by following a previously described procedure.  
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2.4.3 Synthesis of Nanogel-Streptavidin 
Streptavidin maleimide was purchased from Acros, and its structure is shown below 
in Figure 24. The maleimide end can be attached to a thiol group that linkes to the 
nanogel.  The amine end of the nanogel was firstly attached with a ligand that had 
carboxyl function group at one end and a protected thiol group at the other end.  
streptavidin
H
N
O
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O
O
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Figure 24 Structure of streptavidin Maleimide 
The conversion of 5-bromopentanoic acid to 5-(carbamimidoylthio) pentanoic acid 
was achieved by reacting 5-bromopentanoic acid with thiourea in refluxing acetone 
overnight.53 The white solid product  precipitated out of solution after the reaction 
was cooled down to room temperature. Washing with cold acetone gave desired 
compound as a pure product. 5-(carbamimidoylthio) pentanoic acid (53) reacted with 
sodium hydroxide at 90 ºC followed by acidic aqueous work up using sulfuric acid to 
 - 74 - 
produce thiol compound 54 as the product. Since the thiol was not stable, it was 
protected with trityl (Trt) group using potassium hydroxide and triphenylmethyl 
chloride in ethanol to yield 55. 
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The carboxyl end of the thiol compound was directly attached to the nanogel using N, 
N’-dicyclohexylcarbodiimide (DCC) as a coupling reagent in dichloromethane. Thin 
layer chromatography (TLC) using 4:4:1 hexane: dichloromethane: diethyl ether as the 
elution solvent indicated the disappearance of UV active thiol compound 55 (Rf =0.4). 
A new UV active spot was formed which had a Rf=0.8. The dialysis in 10% of ethanol 
in water afforded the desired compound 56 as a white powder after lyophilization. 
Rhodamine dye was attached to the nanogel using freshly prepared activated 
rhodamine in DMF. Dialysis and lyophilizaion using an analogous procedure as 
described earlier gave compound 57 as a red powder.  
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  After the rhodamine was attached to the thio-nanogel, the next step involved 
deprotection of the thiol group and attachment of streptavidin. Compound 57 was 
treated with triisopropylsilane and trifluoroacetic acid in dichloromethane to remove 
the trityl group. The thiol intermediate was not isolated and was treated immediately 
with streptavidin maleimide. This was done due to the instability of thiol side chain. 
After the removal of solvent, the residue was dialyzed in a 10% of ethanol in water 
solution followed by lyophilization to give compound 59 as a pink powder.   
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2.4.4 Results and Discussion 
   Stem cells were loaded with biotinylated nanogels. The results indicated that 
biotinylated nanogel (49) was not toxic against the stem cells. It could be served as a 
carrier for the anti-cancer drugs that target at the biotin receptor site of the cancer cells. 
However, biotinylated nangoel 49 can not internalize into the stem cells. Therefore, 
Nanogel-Streptavidin (59) was investigated. 
 
 
Figure 25 cell viabilities of RUCs loaded with biotinylated nanogels (49) RUCswere 
seeded in a 96 well plate and after reaching 70% confluency, the media was replaced 
with fresh medium containing nanogel 49 and/or biotin. Following incubation for 72 
hours cell proliferation assays were performed every 24 hours.  
 
Neural stem cells (NSC) were treated with Nanogel-Streptavidin (59). After 15 
minutes, the confocal image was taken and the results indicated that the nanogels were 
loaded into the neural stem cells with a high loading efficiency. Figure 26 clearly 
shows the red nanogels internalized into the blue neural stem cells. When compared to 
all the type I and type II nanogels which took at least 12 hours to internalized into stem 
cells with a low loading efficiency, this type III nanogel had many benefits. Firstly, the 
much shorter loading time reduced the cytotoxicity of nanogels to the stem cells. 
Secondly, the shorter loading time also reduced the possibility of the release of 
anticancer drugs before reaching the tumor target. Since most of our nanogels would 
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release the drugs in about 2 days; a higher loading efficiency increased the loading 
ability of the stem cells and therefore decreases the drug dosage and minimizing the 
cytotoxicity of our nanogels. 
 
Figure 26 Stem cells (blue) loaded with nanogel-streptavidin (red) in 15mins 
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2.5 Conclusion 
To deliver the anticancer drug to the cancer cells, a system that makes use of 
nontoxic nanogels and stem cells was developed. The nanogel served as a drug 
encapsulation material, and stem cells served as a targeting vehicle that could 
specifically target at the tumor site. 
Type I nontoxic PEG-PEI nanogel was successful synthesized via a double treatment 
of PEI with activated PEG. The encapsulation of type I nanogel with anticancer drug 
(AQ10) enhanced the solubility of anticancer drug and consequently decreased the 
dosage. The sizes of the nanogel was characterized by AFM and found to be 
approximately 20 nm. This nanogel can be loaded into stem cells with low cytotoxicity 
and delivered to the tumor target.  
To further enhance the toxicity, anticancer drug (SN38) was attached to the outside 
of Type II nanogel along with a tetrapeptide that cleavable by legumain as well as the 
encapsulation into inside of the nanogel. A tetra-peptide linker that can be recognized 
and cleaved by legumain to release the anticancer drug was attached. The results 
demonstrated a enhanced bioactivity against the cancer cells. 
Streptavidin was attached to type III nanogels. Nanogel-Streptaividin can be loaded 
into neural stem cells within 15 minutes which significantly reduced the loading time 
compared to other nanogels. 
  The future work would be focused on the streptavidin nanogels (type III), new 
anticancer reagent will be encapsulated into type III nanogel and the bioactivities will 
be investigated. 
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2.7 Experimental Section 
Separation of PEI 
A chromatographic column was packed using Sephacryl S200, flashed with deionized 
water. 7.0 g (0.28 mmol) of PEI (MW ~25 kDa) was dissolved in 20 ml of deionized 
water and loaded to the column. Deionized water was used as eluant by gravity, no 
additional pressure was applied. After 6 hours, the middle fractions were collected to 
give 3.64 g (0.146 mmol) of PEI (MW ~25 kDa). 1H NMR (D2O) δ 2.72 (bs, CH2N), 
2.68 (bs, CH2N); the number of hydrogens cannot be determined from integration due 
to the overlap of two signals above. 
 
Activation of PEG   
To a solution of 2.0 g (0.25 mmol) of PEG (MW 8 kDa) in 7 mL of dry acetonitrile 
under argon was added 0.41 g (2.5 mmol) of 1,1’-carbonyldiimidazole, and the 
solution was stirred at 40oC for 2 hours.  The crude product was purified by dialysis 
using a MWCO 3500 Dalton membrane twice with 1000 mL of 10% ethanol in 
deionized water at 4oC for 4 hours.  The solution was lyophilized to give 1.84 g of 
activated PEG.  1H NMR (CDCl3) δ 7.69 (s, 1 H, ArH), 7.11 (s, 2 H, ArH), 3.62 (s, 
190 H, CH2O). 
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Preparation of nanogel PEG-PEI (28) 
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 Nanogel (polyethyleneglycol)-(polyethylenimine) [NG(PEG)(PEI)] (the molecular 
weight of PEG is ~8 kDa and that of PEI is ~25 kDa) was prepared by following a 
similar micellar method (Vinogradov et al., 2006) starting from activated polyethylene 
glycol (activation with 1,1’-carbonyldiimidazole; ~125 µmol were used) and 
polyethylenimine (PEI; ~40 µmol were used) (Scheme 1). To a solution of 1.0 g (40 
µmol) of PEI (MW ~25 kDa) in 300 mL of deionized water was added dropwise a 
solution of 1.0 g (125 µmol) of activated PEG (MW ~8 kDa) in 2 mL of 
dichloromethane. The solution turned to a white suspension due to the heterogeneous 
solvent system. The white suspension was sonicated in a water bath for 15 minutes; 
longer sonication did not improve the quality of nanogel. The organic solvent 
dicholoromethane was removed on a rotary evaporator resulting in a transparent 
solution.  The solution was dialyzed with a 12K – 14K MWCO membrane in 1000 
mL of 10% ethanol in deionized water for 1 day at 25oC and lyophilized to give 
nanogel PEG-PEI.  This nanogel was again treated with 1.0g (125 µmol) of activated 
PEG in 2 mL of dichloromethane and worked up as that mentioned above to give 1.32 
g of nanogel PEG-PEI as a white powder.  1H NMR (D2O) δ 3.70 (s, area 44, CH2O), 
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3.40 – 2.60 (m, area 6.5, CH2N).  Based on the weight of the product, we estimate that 
the molecular weight of the nanogel is ~33 KDa (for each mole of PEI, one mole of 
PEG is added).  The initial treatment of PEI with activated PEG provided a partial 
cross-linkage of PEG, in which for each mole of PEI, there is ~ 0.5 mole of PEG 
attached.  This partial linking PEG-PEI is toxic to stem cells. 
 
Synthesis of aceterylated nanogel PEG-PEI (27) 
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To a solution of 100 mg 1:4 ratio of CH2N:CH2O nanogel in 1 ml acetonitrile under 
argon, was added 200 µL of acetic anhydride at room temperature. The resulting was 
stirred at 50oC for 12 hours, cooled to 25oC, dialyzed with a 12k – 14 kDa MWCO 
membrane in 100 ml of 10% ethanol in deionized water at room temperature for 1 day, 
and lyophilized to give 103 mg of aceterylated nanogel as a white powder. 
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Synthesis of nanogel PEG-PEI-rhodamine(29) 
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To A mixture of 15 mg (32 µmol) of 6-Carboxytetramethylrhodamine (TAMRA), 6.52 
mg (48 µmol) of HOBT, 9.9 mg (48 µmol) of DCC and 4.44 mg (39 µmol) of 
N-hydroxysuccinimide under argon, 1 mL of dry DMF was added via syringe at 25oC.  
The resulting solution was stirred at 50-55oC for 2.5 hours, cooled to room temperature, 
and added a solution of 400 mg of nanogel PEG-PEI in 1mL of dry acetonitrile.  The 
solution was stirred at 40oC for 12 hours, cooled to 25oC, dialyzed with a 12k - 14kDa 
MWCO membrane in 1000 ml of 10% ethanol in deionized water at room temperature 
for 1 day, and lyophilized to give 186 mg of PEG-PEI-rhodamine as a pink powder.  
1H NMR (D2O) δ 8.50 (s, area 0.03), 8.10 (m, area 0.015), 7.90 (m, area 0.015), 7.73 
(m, area 0.015), 7.37 (m, area 0.06), 3.70 (s, area 100, CH2O), 3.20 – 2.60 (m, area 
14.7, CH2N).  UV-vis (H2O), λmax = 557 nm and εmax = 1.57 x 104 M-1•cm-1 (assuming 
the MW ~33 KDa). 
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Inclusion of AQ10 (1%) in Nanogel PEG-PEI-rhodamine 
AQ10
AQ10-NG-Rh
31
 
To a solution of 50 mg of PEG-PEI-rhodamine in 5 mL of deionized water, was added 
0.5 mg (2.1 µmol) of AQ10 in 1 mL of acetonitrile.  The resulting solution was 
lyophilized to give 50.5 mg of PEG-PEI-rhodamine-AQ10 as a pink powder. Inclusion 
of 5% AQ10 was done by the similar method describe above. 
 
TBDPS-SN38 (36) 
N
N
O
O
OOH
TBDPSO
 
 
To a suspension of 60 mg (0.15 mmol) SN38 in 10 ml distilled dichloromethane under 
argon, were added 300 µL t-butyl-diphenylsilyl chloride and 300 µL triethylamine at 
room temperature. The reaction was heated up to reflux for 12 hours. A greenish 
solution was resulted. After cooled down to room temperature, the solution was diluted 
with 20 ml dichloromethane and washed with 20 ml 0.1N HCl, 20 ml 1% sodium 
bicarbonate, 20 ml water and 20 ml brine respectively. The organic layer was dried 
over MgSO4 and concentrated. Crude product was purified by a silica gel column 
chromatography using 80:2 dichloromethane and methanol as eluants to give 96 mg 
(100%) of compound 2.2 :1H NMR(400 MHz, CDCl3): δ (t, J=7.6Hz, 3Η), 1.02 (t, 
J=7.4Hz, 3H), 1.18(s, 9H), 1.83-1.93(m, 2H), 2.64(q, J=7.6Hz, 2H), 3.68(s, 1H), 
5.12(s, 2H), 5.26(d, J=15.6Hz, 1H), 5.71(d, J=16.4Hz, 1H), 7.08(d, J=2.5Hz, 2H), 
7.35-7.49(m, 7H), 7.57(s, 1H), 7.76-7.78(m, 4H), 8.05(d, J=9.2Hz, 1H).  
 
 
 - 90 - 
TBDPS-SN38-Gly-Boc (37) 
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To a solution of 75 mg (0.12 mmol) of compound 2.2 and 42 mg (0.24 mmol) of 
Boc-Gly-OH in 5 ml distilled dichloromethane under argon at 0, were added 46 mg 
(0.24 mmol) of N-ethyl-N’- (3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC) and 8 mg (0.06 mmol) of 4-Dimethylaminopyridine (DMAP). The solution was 
stirred at 0 for 12 hours. After warm up to room temperature, the solution was diluted 
with 20 ml of dichloromethane, and then washed with 1% sodium bicarbonate, water, 
0.1N HCl and water respectively. The organic layer was washed with brine and dried 
over MgSO4, concentrated and vacuum dried to give 90 mg (96%) of compound 37: 1H 
NMR(400 MHz, CDCl3): δ 0.88 (t, J=7.8Hz, 3H), 0.96 (t, J=7.6Hz, 3H), 1.18(s, 9H), 
1.40(s, 9H), 2.10-2.31(m, 2H), 2.65 (q, J=7.6Hz, 2H), 3.64 (s, 2H), 5.10 (d, J=1.9Hz, 
2H), 5.37 (d, J=17.0Hz, 1H), 5.66(d, J=17.0Hz, 1H), 7.08 (s, 1H), 7.12 (d, J=2.4Hz, 
1H), 7.37-7.50 (m, 7H), 7.75(d, J=6.6Hz, 4H), 8.02 (d, J=9.2Hz, 1H). 
 
TBDPS-SN38-Gly (38) 
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A solution of 75 mg (0.1 mmol) compound 37 in 2M HCl in dioxane under argon was 
stirred at room temperature for 1 hour. Saturated aqueous sodium bicarbonate solution 
was added until basic after the reaction was done. The aqueous solution was extracted 
with dichloromethane 3 times. The organic extract was washed with brine, dried 
(MgSO4), and concentrated to give 65 mg (99%) of compound 38: 1H NMR(400 MHz, 
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CDCl3): δ 0.89 (t, J=7.8Hz, 3H), 0.96 (t, J=7.6Hz, 3H), 1.17(s, 9H), 2.15-2.31(m, 2H), 
2.65 (q, J=7.6Hz, 2H), 3.64 (s, 2H), 5.10 (d, J=1.9Hz, 2H), 5.37 (d, J=17.0Hz, 1H), 
5.66(d, J=17.0Hz, 1H), 7.08 (s, 1H), 7.12 (d, J=2.4Hz, 1H), 7.36-7.50 (m, 7H), 7.75(d, 
J=6.6Hz, 4H), 8.02 (d, J=9.2Hz, 1H). 
 
TBDPS-SN38-Gly-Succinyl (39) 
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A solution of 50 mg (0.07 mmol) of compound 38 and 11 mg (0.1 mmol) of succinic 
anhydride in 3 ml distilled dioxane under argon was heated up to 90 for 1 hour. After 
cooled down to room temperature, the solution was diluted with 20 ml of 0.1N HCl, 
and then extracted with ethyl acetate 4 times. The organic extract was washed with 
brine, dried (MgSO4), concentrated and column chromatographed on silica gel using 
15:1 dichloromethane and methanol to give 55 mg (96% yield) of compound 39 : 1H 
NMR(400 MHz, CDCl3): δ 0.89 (t, J=7.6Hz, 6H), 1.17(s, 9H), 2.19-2.38 (m, 2H), 
2.60-2.70 (m, 6H), 4.07-4.20 (m, 2H), 5.11 (s, 2H), 5.39 (d, J=17.1Hz, 1H), 5.60 (d, 
J=17.2Hz, 1H), 7.12 (d, J=2.4Hz, 1H), 7.36-7.50 (m, 7H), 7.75(d, J=6.8Hz, 4H), 8.12 
(d, J=9.4Hz, 1H); 13C NMR(200MHz, CDCl3) δ 7.58, 13.38, 19.64, 23.14, 26.60, 
30.10, 31.07, 32.12, 41.75, 49.37, 67.43, 97.11, 110.53, 120.51, 126.70, 127.14, 128.21, 
130.46, 132.07, 135.59, 144.18, 144.77, 145.46, 146.36, 149.23, 155.41, 157.36, 
167.58, 168.63, 171.08, 172.33, 175.68; HRMS calcd for C44H45N3O9SiNa (M+Na+) 
810.2822, found 810.2829. 
 
Resin-Tetrapeptide(Ala-Ala-Asn-Leu) (41) 
 
NH2LeuAsnAlaAla
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To a reaction vessel with 2.4 g (0.2mmol) of Fmoc-Ala-NovaSyn TGA (resin) was 
added 14 ml 20% of piperidine in DMF at room temperature. The reaction vessel was 
set down to the Discover Microwave Peptide Synthesizer. Select and run the 
deprotection program (Temp=75°C, Power=50 W, Time=3 min) twice. After cooled 
down to 50°C, solvent was filtrated and the residue in reaction vessel was washed with 
80 ml of DMF. A freshly prepared solution of 312 mg (1.0 mmol) of Fmoc-Ala-OH, 
380 mg (1.0 mmol) of HBTU (O-Benzotriazole N,N,N',N'-tetramethyl uronium 
hexafluoro phosphate) and 0.33 ml diisopropylethyl amine in 8 ml of DMF was added 
to the reaction vessel with deprotected resin alanine inside. Select and run the coupling 
program (Temp=75°C, Power=25W, Time=5min) twice. After cooled down to 50°C, 
filter off the solvent and wash the solid with 80 ml DMF. Fmoc-Asn(Trt)-OH and 
Fmoc-Leu-OH were attached to the resin similarly by following the same deprotection 
and coupling procedure. After the final deprotection of Fmoc at the leucine end, the 
solvent was removed and resin-peptide was washed with 80 ml of dichloromethane 
instead of DMF. 
 
Tetrapeptide-SN38 (43) 
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To a reaction vessel with 0.05 mmol resin-peptide, were added a freshly prepared 
solution of 45 mg (0.06 mmol) compound 39 and 190 mg (0.5 mmol) of HBTU in 10 
ml DMF and 500 µL diisopropylethyl amine. The reaction vessel was put in the 
microwave peptide synthesizer. Run the SN38 program (Temp=80°C, Power=60 W, 
Time=60 min). The yellow solution turned to brown after cooled down to 50°C. The 
organic solution was filtered off; and the resin solid was washed with 100 ml of 
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dichloromethane. A freshly prepared cleavage solution with 250 µL of 
triisopropylsilane and 250 µL of water in 9.5 ml trifloroacetic acid was added to the 
reaction vessel. Run the cleavage program (Temp=38°C, Power=20W, Time=18 min). 
After cooled down to room temperature, the cleavage solution was collected by 
filtration; and the resin solid was washed with 4 ml of dichloromethane twice which 
was combined to the cleavage solution. The solvent was removed on the rota-vapor. A 
silica gel column chromatography using hexane, ethyl acetate and methanol as 
solvents gave 30 mg of compound 43 as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 
0.90 (t, J=7.6Hz, 3H), 0.98 (t, J=7.4Hz, 3H), 1.11-1.33 (m, 6H), 1.18 (s, 9H), 1.50-1.73 
(m, 6H), 1.87 (m, 2H), 2.04-2.23 (m, 2H), 2.63 (m, 8H), 3.59 (m, 2H), 4.07 (m, 2H), 
4.14-4.37 (m, 2H), 5.13 (s, 2H), 5.33 (d, J=17.1Hz, 1H), 5.63 (d, J=17.2Hz, 1H), 7.12 
(d, J=2.4Hz, 1H), 7.36-7.50 (m, 7H), 7.75(d, J=6.8Hz, 4H), 8.18 (s, 1H). 
 
Nanogel-Tetrapeptide-SN38 (44) 
N
N
O
O
OO
HO
N
H O
O
O
H
NLeuAsnAlaAla
O
H
N
n
 
 
To a solution of 20 mg (0.017 mmol) of peptide-SN38, 16 mg (0.083 mmol) of 
N-ethyl-N’-(3-dimethylamino- propyl)  carbodiimide hydrochloride (EDC) and 16 
mg (0.131 mmol) of 4-Dimethylaminopyridine (DMAP) in 10 ml of dichloromethane 
at 0°C under argon, was added 60 mg of nanogel 28 (PEG:PEI=6.8:1, nontoxic). The 
solution was stirred at 0°C for 4 hours and then heated up to 40°C for 12 hours. After 
cooled down to room temperature, the solvent was removed on a rota-vapor. The 
residue was dissolved again in 5 ml of ethanol and dialyzed in 1000 ml of 10% ethanol 
in water at room temperature for 24 hours using a 3500 Dalton molecular weight cut 
off membrane. Lyophilization gave 70 mg of compound 44. 1H NMR (400 mHz, D2O) 
δ 0.9−1.4 (m, CH3 of amino acids and SN38, t-butyl of SN38), 1.9-2.1 (m, CH-C=O of 
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amino acids and SN38), 2.4-3.2 (m, CH2 of PEI and SN38), 3.6-3.9 (m, CH2 of PEG), 
6.8-6.9 (Ar-H), 7.2 (Ar-H). 
 
Nanogel-SN38-Tetrapeptide-SN38 (45) 
N
N
O
O
OO
HO
N
H O
O
O
H
NLeuAsnAlaAla
O
H
N
n
SN38
 
To a solution of 60 mg compound in 15 ml of diionized water, was added a 
suspension of 3 mg (5% by weight to nanogel) of SN38 in 2 ml of ethanol. The 
combined solution was stirred for 1 minute and lyophilized immediately to give 63 mg 
of product. 1H NMR (400 MHz, D2O) δ 0.9−1.4 (m, CH3 of amino acids and SN38, 
t-butyl of SN38), 1.9-2.1 (m, CH-C=O of amino acids and SN38), 2.4-3.2 (m, CH2 of 
PEI and SN38), 3.6-3.9 (m, CH2 of PEG), 6.8-6.9 (Ar-H), 7.2 (Ar-H). 
 
Activation of Biotin (47) 
 
NHHN
S
O
HH
O
O
N
O
O
 
To a solution of 400 mg (1.64 mmol) biotin in 12 ml of DMF, 200 mg (1.74 mmol) of 
DCC and 340 mg (1.65 mmol) of NHS were added at room temperature under argon. 
The mixture was stirred at room temperature for 3 hours. White precipitates came out 
and was filtered off to obtain a transparent solution. 100 ml of diethyl ether was added 
to the crude solution to precipitate out the activated biotin. After dried under vacuum 
for 24 hours, 390 mg (70%) of activated biotin was obtained. 1H NMR (200 MHz, 
DMSO-D6) δ 1.43-1.64 (m, 6H, CH2-C), 2.67 (t, J=7.3Hz, 2H), 2.81 (s, 4H), 3.11 (d, 
J=11.7Hz, 2H), 3.35 (s, 1H), 4.15 (d, J=4Hz, 1H), 4.27 (t, J=4.8Hz, 1H), 6.39 (s, 1H, 
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N-H), 6.45 (s, 1H, N-H). 
 
Biotinylated Nanogel (48) 
 
NHHN
S
O
HH H
N
O
*
m
* NH2 l
 
To a solution of 100 mg nontoxic nanogel 28, a solution of 3 mg (8.8 µmol) of 
activated biotin in 1 ml of DMF was added at room temperature under argon. The 
mixture was stirred at 50°C for 24 hours, dialyzed with 1000 ml of 10% ethanol in 
diionized water at room temperature using a 12kDa-14kDa molecular weight cut off 
membrane, and lyophilized to give 98 mg of biotinylated nanogel as a light green 
powder. 1H NMR (400 MHz, D2O) δ 0.88 (CH2), 1.09 (CH2), 2.60-2.95 (CH2-N), 
3.70-3.98 (CH2-O), 7.12 (s, N-H), 7.48 (s, N-H). 
 
Rhodamine attached Biotinylated Nanogel (49) 
NHHN
S
O
HH H
N
O
*
m
* NH2 p
Rh
52
 
Activated rhodamine dye was attached to the biotinylated nanogel by following a 
similar procedure described above. 
To A mixture of 15 mg (32 µmol) of 6-Carboxytetramethylrhodamine (TAMRA), 
6.52 mg (48 µmol) of HOBT, 9.9 mg (48 µmol) of DCC and 4.44 mg (39 µmol) of 
N-hydroxysuccinimide under argon, 1 mL of dry DMF was added via syringe at 25oC.  
The resulting solution was stirred at 50-55oC for 2.5 hours, cooled to room temperature, 
and added a solution of 100 mg of biotinylated nanogel (48) in 1mL of dry acetonitrile.  
The solution was stirred at 40oC for 12 hours, cooled to 25oC, dialyzed with a 12k - 
14kDa MWCO membrane in 1000 ml of 10% ethanol in deionized water at room 
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temperature for 1 day, and lyophilized to give 100 mg of PEG-PEI-rhodamine as a pink 
powder.   
 
5-(carbamimidoylthio) pentanoic acid53 (53) 
S OH
ONH
H2N
 
To a solution of 3.0 g (16.6 mmol) of 5-bromopentanoic acid in 150 ml of distilled 
acetone, was added 0.6 g (7.9 mmol) of thiourea at room temperature. The solution 
was heated up to reflux for 12 hours. White precipitates came out when cooled down to 
room temperature. The solvent solution was filtered off; and the remaining white solid 
was washed with cold acetone. 1.3 g (93.5%) of 5-(carbamimidoylthio) pentanoic acid 
was obtained. 1H NMR (200MHz, DMSO-D6) δ 1.55 (t, J=3.3Hz, 4H), 2.23 (t, 
J=6.6Hz, 2H), 3.17 (t, J=6.6Hz, 2H), 8.99 (d, J=22.3H, 3H); 13C NMR δ  174.34, 
170.00, 33.03, 29.97, 28.00, 23.34. 
 
5-mercaptopentanoic acid (54) 
HS OH
O
 
To a solution of 1.2 g (6.8 mmol) of 5-(carbamimidoylthio) pentanoic acid in 13 ml 
of water, was added 4.08 g (102 mmol) of sodium hydroxide at room temperature. The 
solution was heated up to reflux for 24 hours. After the solution cooled down to room 
temperature, 2M sulfuric acid was added until acidic (pH=2). The solution was 
extracted with dichloromethane 4 times; the combined organic extract was washed 
with sodium thiosulfate and brine, and then dried over magnesium sulfate. The solvent 
was removed on rota-vapor to give 720 mg (79%) of 5-mercaptopentanoic acid. 1H 
NMR (200MHz, CDCl3) δ 1.32 (t, J=6.9Hz, 1H, SH), 1.60-1.80 (m, 4H, 2CH2), 2.37 (t, 
J=6.9Hz, 2H, CH2-C=O), 2.50 (q, J=6.6Hz, 2H, CH2-S); 13C NMR δ 180.19, 33.64, 
33.33, 24.31, 23.43. 
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5-(tritylthio)pentanoic acid (55) 
S OH
O
Ph3C
 
To a solution of 80 mg (0.6 mmol) of 5-mercaptopentanoic acid 54 in 10 ml distilled 
ethanol at room temperature under argon, was added 100 mg (1.8 mmol) of potassium 
hydroxide. The solution was stirred at room temperature for 20 min. 335 mg (1.2 mmol) 
of chlorotriphenyl- methane was added. The solution was stirred at room temperature 
for 12 hours and then diluted with 20 ml of water, acidified with 2M sulfuric acid, 
extracted with ethyl acetate. The organic extract was washed with brine and dried over 
magnesium sulfate. Solvent was removed on a rota-vapor. The crude product was 
applied to a silica gel column chromatography using hexane, ethyl acetate and 
methanol as eluants. 100 mg (44%) of compound 55 was obtained as oil. 1H NMR (400 
MHz, CDCl3) δ 1.40 (p, J=7.2Hz, 2H), 1.58 (p, J=7.2Hz, 2H), 2.14-2.22 (m, 4H), 
7.20-7.42(m, 15H, Ar-H). 
 
Nanogel-Thiolinker (56) 
S NH
O
Ph3C
*
n
 
To a solution of 20 mg (0.05 mmol) of 5-(tritylthio)pentanoic acid in 3 ml of distilled 
dichloromethane under argon, was added 20 mg (0.1 mmol) of 
N,N’-dicyclohexylcarbodiimide (DCC). The solution was stirred at room temperature 
for 12 hours and turned to a white suspension. 50mg of nanogel 28 (PEG: PEI=6.8:1, 
nontoxic) was added to the suspension and stirred for 12 hours at room temperature. 
Thin layer chromatography indicated the disappearance of 5-(tritylthio)pentanoic acid; 
and the reaction was stopped. The solvent was removed on rota-vapor. The residue was 
dissolved in 10ml of water and dialyzed in 1000 ml of 10% ethanol in water at room 
temperature for 24 hours using a 3500 Dalton molecular weight cut off membrane. 
Lyophilization gave 35 mg of product. 1H NMR (200 MHz, CDCl3) δ 1.32 (CH2), 1.75 
(CH2), 2.10-2.80 (CH2-N), 23.65-3.72 (CH2-O), 7.25-7.40 (Ar-H). 
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Nanogel-Thiolinker-Rhodamine (57) 
S NH
O
Ph3C
*
n
* Rh n0
 
To A mixture of 3 mg (6 µmol) of 6-Carboxytetramethylrhodamine (TAMRA), 1.3 
mg (9 µmol) of HOBT, 2 mg (9 µmol) of DCC and 0.9 mg (8 µmol) of 
N-hydroxysuccinimide under argon, 0.2 mL of dry DMF was added via syringe at 25oC.  
The resulting solution was stirred at 50-55oC for 2.5 hours, cooled to room temperature, 
and added to a solution of 35mg of compound in 2ml of DMF. The mixture was stirred 
for 12 hours at 40 oC, cooled to 25oC, dialyzed with a 3500 Dalton molecular weight 
cut off membrane in 1000ml of 10% ethanol in deionized water at room temperature 
for 1 day, and lyophilized to give 35 mg of PEG-PEI-rhodamine as a pink powder. 
 
Nanogel-Rhodamine-Thiolinker-Streptavidin (59) 
 
S NH
O
*
n
* Rh n0
N
O
O
H
N
O
streptavidin
 
To a solution of 35 mg of compound in 8 ml of dichloromethane at room temperature 
under argon, 300 µL of trifloroacetic acid and 300 µL of triisopropylsilane were added. 
The color of the solution turned from pink to red upon the adding. The mixture was 
stirred at 25oC for 2 hours, and added to a solution of 2 mg streptavidin maleimide in 2 
ml of dichloromethane, stirred at room temperature for 12 hours. The mixture was then 
dialyzed in 1000 ml of 10% ethanol in water using a 12-14kDa molecular weight cut 
off membrane at 25oC for 24 hours, and lyophilized to give 30 mg of pink powder. 
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Appendices: 1H and 13C NMR spectra 
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